Spectral AI Announces 2026 Third Quarter Financial Results

Remains on Track for First U.S. Commercial Placement of the DeepView AI System in the Fourth Quarter of 2026

DALLAS, Nov. 10, 2026 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reported financial results for the third quarter ended September 30, 2026 (“Q3 2026”). The Company expects to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 on or before November 16, 2026.

“Our third-quarter results reflect our continued transition from a research and development organization into a commercial enterprise,” said Vincent Capone, Chief Executive Officer. “We have begun manufacturing the first 30 DeepView AI Systems for BARDA-supported deployment at U.S. burn centers and remain on track for initial deliveries by year-end. While executing on our near-term priorities, we are taking a long-term view of the DeepView AI System, looking beyond early deployments to build the capabilities that will support broader adoption and establish a repeatable clinical model. These include clinician education, pursuing expanded reimbursement for physicians and hospital systems, and exploring label expansion opportunities. We are encouraged by the response from the clinical community thus far, including at the Southern Regional Burn Conference, where leading burn surgeons presented new study results using DeepView AI, and at the American College of Emergency Physicians’ annual conference in October.”

“During the third quarter, we reduced operating expenses by 4% from a year ago while continuing to fund the development of our technology and support our commercial launch activities,” said David McGuire, Chief Financial Officer of Spectral AI. “We ended the quarter with $11.2 million of cash, and we are assessing opportunities to strengthen our balance sheet as we move from development to commercialization.”

Third Quarter and Recent Business Highlights

  • Presented the DeepView AI System at the Southern Regional Burn Conference, including presentations on physician accuracy in identifying non-healing burns and on the repeatability and reproducibility of the AI analysis.
  • Completed all Site Initiation Visits with four burn centers in the United Kingdom and have enrolled ten patients in our clinical study designed to support a label expansion of the DeepView AI System to include burns involving the head, hands and feet.
  • Submitted a New Technology Add-On Payment (NTAP) application to the Centers for Medicare & Medicaid Services (CMS) for the DeepView AI System which, if approved, would provide hospitals with additional Medicare reimbursement for use of the DeepView AI System. A determination is expected by August 2027.
  • Showcased the DeepView AI System for burn indication at the American College of Emergency Physicians (ACEP) Scientific Assembly in Chicago, October 5–8, 2026.

Third Quarter 2026 Financial Results


All comparisons are to the third quarter ended September 30, 2025 (“Q3 2025”), unless otherwise noted

Research and development revenue was $2.9 million for Q3 2026 compared to $3.8 million, a decrease of 24.7%. BARDA revenue was $2.7 million compared to $3.4 million, reflecting the cost-share structure of the current phase of the BARDA Project BioShield contract. This phase of the BARDA Project BioShield contract requires the Company to fund a portion of follow-on development expenses for the DeepView AI System, which was advanced following the receipt of FDA De Novo Clearance for the DeepView AI System in May 2026.

Revenue from other U.S. government programs, principally the MTEC handheld device program, was $0.1 million, compared to $0.4 million, as the MTEC program was completed.

Gross margin was 27.2% for Q3 2026 compared to 42.7%, primarily reflecting the Company’s share of development costs under the BARDA cost share, which is included in cost of revenue.

Operating expenses were $4.7 million for Q3 2026 compared to $5.0 million, a decrease of 4.4%. General and administrative expense decreased to $2.3 million from $3.1 million, primarily reflecting lower legal fees and related professional services. Research and development expense increased to $2.0 million from $1.5 million, reflecting increased non-revenue-generating development activities, primarily from the costs associated with the Company’s UK label expansion study for burns involving the head, hands and feet. Selling and marketing expense was $0.4 million, an increase of 12.8%, reflecting expanded commercialization activities ahead of the launch of the DeepView AI System.

Other income was $0.2 million for Q3 2026 compared to other expense of $(0.2) million, due primarily to a $0.8 million gain from the change in fair value of warrant liabilities, partly offset by $0.6 million of net interest expense on the Company’s credit facility.

Net loss was $(3.7) million, or $(0.11) per share, for Q3 2026, compared to $(3.6) million, or $(0.13) per share. Q3 2026 included a $0.1 million income tax benefit related to Texas franchise tax.

Adjusted EBITDA, a non-GAAP measure, was $(3.7) million for Q3 2026, compared to $(3.1) million. A reconciliation of net loss to Adjusted EBITDA is included in the statements below.

Balance Sheet and Liquidity

Cash and cash equivalents were $11.2 million at September 30, 2026, compared to $15.4 million at December 31, 2025.

2026 Guidance

The Company is updating its guidance for the year ending December 31, 2026, and now expects research and development revenue of approximately$13.0 million, compared to its previous guidance of approximately $18.5 million. The updated guidance primarily reflects the completion of the MTEC program with no additional contracting opportunities in 2026, and the timing of research and development activities reimbursed under the BARDA contract, which moves revenue into future periods within the existing contract term.

This updated guidance does not include revenue from sales of the DeepView AI System, the first of which the Company expects to place by year-end 2026, or any new or extended government awards.

Conference Call

Spectral AI will host a conference call today at 5:00 p.m. Eastern Time to discuss its third quarter 2026 financial results. Investors may dial 833-890-6620 (U.S.) or 412-564-3789 (international). A simultaneous webcast will be available in the Events section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events, and a replay will be available following the call.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView AI System. The DeepView AI System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView AI System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. For more information about the DeepView AI System, visit www.spectral-ai.com.

The Company’s contract with the Biomedical Advanced Research and Development Authority (“BARDA”) is held and performed through its wholly owned subsidiary, Spectral MD. References to the contract, associated awards, related revenue, business opportunities, obligations, and other relevant factors should be understood to refer to Spectral MD as the contracting party unless otherwise indicated.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the Company’s updated 2026 revenue guidance, the expected timing of first commercial sales of the DeepView AI System, the timing and outcome of the Company’s NTAP application, the continued funding and exercise of options under the BARDA contract, and the Company’s liquidity, capital requirements and ability to meet its debt obligations. Actual results may differ materially from those indicated by these statements as a result of various factors, including those described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Non-GAAP Financial Measures

This press release includes Adjusted EBITDA, a financial measure not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). The Company defines Adjusted EBITDA as net loss before income taxes, depreciation and net interest expense, further adjusted to exclude stock-based compensation, financing related costs, changes in the fair value of warrant liabilities and notes payable, foreign exchange transaction gains and losses, and transaction costs. Management uses Adjusted EBITDA to evaluate the Company’s operating performance and believes it provides useful information to investors. Adjusted EBITDA has limitations as an analytical tool: it does not reflect recurring interest expense, stock-based compensation, income taxes, capital expenditures or working capital needs, and it should not be considered in isolation or as a substitute for net loss or other measures prepared in accordance with GAAP. A reconciliation of net loss to Adjusted EBITDA is included below.

Investor Contacts

The Equity Group

Devin Sullivan, Managing Director, (212) 836-9608, [email protected]
Conor Rodriguez, Associate, (212) 836-9628, [email protected]

Spectral AI, Inc.

[email protected] | +1 972 499-4934 | 2515 McKinney Avenue, Suite 1000, Dallas, Texas 75201

SPECTRAL AI, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)


 
  September 30,
2026
December 31,
2025
  (unaudited)  
Assets    
Current assets:    
Cash and cash equivalents 11,230   15,394  
Accounts receivable, net 1,313   1,267  
Inventory 932   838  
Prepaid expenses 890   821  
Other current assets 761   1,133  
Total current assets 15,126   19,453  
Non-current assets:    
Property and equipment, net 168   258  
Right-of-use assets 955   1,407  
Other assets 310   287  
Total assets 16,559   21,405  
Liabilities and Stockholders’ Deficit    
Current liabilities:    
Accounts payable 1,551   3,010  
Accrued expenses 2,287   2,341  
Deferred revenue 570   154  
Lease liabilities, short-term 798   734  
Notes payable 8,026   2,854  
Warrant liabilities 10,956   11,533  
Total current liabilities 24,188   20,626  
Notes payable, long-term 7,440   5,538  
Lease liabilities, long-term 359   968  
Total liabilities 31,987   27,132  
Commitments and contingencies    
Stockholders’ deficit:    
Preferred stock ($0.0001 par value; 1,000,000 shares authorized; none issued and outstanding) —   —  
Common stock ($0.0001 par value; 80,000,000 shares authorized; 32,184,928 and 30,688,895 shares issued and outstanding, respectively) 3   3  
Additional paid-in capital 51,578   50,030  
Accumulated other comprehensive income 35   40  
Accumulated deficit (67,044 ) (55,800 )
Total stockholders’ deficit (15,428 ) (5,727 )
Total liabilities and stockholders’ deficit 16,559   21,405  

SPECTRAL AI, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; in thousands, except share and per share data)


 
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2026
2025
2026
2025
Research and development revenue 2,856   3,792   10,371   15,564  
Cost of revenue (2,078 ) (2,171 ) (6,453 ) (8,485 )
Gross profit 778   1,621   3,918   7,079  
Operating expenses:        
Research and development 1,989   1,531   5,247   4,301  
General and administrative 2,341   3,064   7,657   8,124  
Selling and marketing 414   367   1,275   1,014  
Total operating expenses 4,744   4,962   14,179   13,439  
Operating loss (3,966 ) (3,341 ) (10,261 ) (6,360 )
Other income (expense):        
Net interest expense (586 ) (464 ) (1,401 ) (881 )
Financing related costs (1 ) —   (13 ) (585 )
Change in fair value of warrant liability 825   264   534   (932 )
Change in fair value of notes payable —   —   —   220  
Foreign exchange transaction loss, net (6 ) (9 ) (21 ) (31 )
Total other income (expense), net 232   (209 ) (901 ) (2,209 )
Loss before income taxes (3,734 ) (3,550 ) (11,162 ) (8,569 )
Income tax provision 78   (2 ) (82 ) (54 )
Net loss (3,656 ) (3,552 ) (11,244 ) (8,623 )
Net loss per share, basic and diluted (0.11 ) (0.13 ) (0.35 ) (0.34 )
Weighted-average common shares outstanding, basic and diluted 32,184,928   26,318,624   32,010,910   25,147,179  

SPECTRAL AI, INC. AND SUBSIDIARIES
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (NON-GAAP)

(unaudited; in thousands)


 
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2026
2025
2026
2025
Net loss (3,656 ) (3,552 ) (11,244 ) (8,623 )
Adjust:        
Depreciation expense 30   30   90   42  
Provision for income taxes (78 ) 2   82   54  
Net interest expense 586   464   1,401   881  
EBITDA (3,118 ) (3,056 ) (9,671 ) (7,646 )
Additional adjustments:        
Stock-based compensation 276   261   1,266   872  
Financing related costs 1   —   13   585  
Change in fair value of warrant liability (825 ) (264 ) (534 ) 932  
Change in fair value of notes payable —   —   —   (220 )
Foreign exchange transaction loss, net 6   9   21   31  
Adjusted EBITDA (3,660 ) (3,050 ) (8,905 ) (5,446 )



StubHub Announces Third Quarter 2026 Results

StubHub Announces Third Quarter 2026 Results

– Gross Merchandise Sales increased to $2.6 billion, up 7% year over year –

– Revenue increased to $502.0 million, up 7% year over year –

– Adjusted EBITDA increased 84%to $124.1 million; adjusted EBITDA margin up 10 percentage points year over year to 25% –

– Raising full-year GMS outlook –

– Further strengthened balance sheet with debt maturity extension at lower borrowing rates and debt reduction –

NEW YORK–(BUSINESS WIRE)–
StubHub Holdings, Inc. (NYSE: STUB), a leading global ticketing marketplace for live events, today reported financial results for the third quarter ended September 30, 2026.

“Consumers continue to prioritize live events and value the trusted experience that StubHub provides as the global market leader,” said Eric Baker, Founder, Chairman and Chief Executive Officer of StubHub. “We are increasing our full-year GMS outlook to reflect our positive third quarter results and anticipated performance for the remainder of the year. Moving forward, we remain committed to advancing StubHub’s strategic priorities that expand access and choice for fans.”

Financial Highlights

  • Gross Merchandise Sales (“GMS”)1 of $2.62 billion, a $181.6 million, or 7% increase compared to $2.43 billion in the prior-year period.

  • Revenue of $502.0 million, or approximately 19% of GMS, a 7% increase compared to $468.1 million in the prior-year period.

  • Net income of $33.6 million, representing a 7% net income margin, compared to a net loss of $1,294.6 million in the prior-year period, which includes $1,405.2 million of stock-based compensation expense.

  • Adjusted EBITDA1 of $124.1 million, representing a 25% adjusted EBITDA margin, an 84% increase compared to $67.5 million in the prior-year period.

  • Cash and cash equivalents of $1.2 billion; payments due to sellers of $0.8 billion.

  • Further strengthened balance sheet by extending its term loan maturities by 3.5 years and reducing borrowing rates in October; repaid $100 million in debt in July.

  • Net leverage1 improved to 2.5x trailing 12-month adjusted EBITDA as of September 30, 2026, a 2.0x reduction compared to 4.5x as of December 31, 2025.

Full Year 2026 Financial Outlook

StubHub is increasing its GMS outlook and reiterating its adjusted EBITDA outlook for full year 2026:

  • GMS of $10.175 billion to $10.375 billion

  • Adjusted EBITDA2 of $400 million to $420 million

These guidance ranges constitute forward-looking statements and reflect information available to the company as of the date hereof. There can be no assurance that the company’s actual results will not differ materially from the estimates set forth, including as a result of factors outside of the company’s control. See cautionary note below regarding “Forward-Looking Statements.”

  1. For definitions and applicable reconciliations, please refer to “Key Business Metric and Non-GAAP Financial Measures” and the tables under “Reconciliations of GAAP to Non-GAAP Financial Measures” below.

  2. A reconciliation of Adjusted EBITDA guidance to the corresponding GAAP measure is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to results computed in accordance with GAAP. For example, stock-based compensation-related charges are impacted by the timing of employee stock transactions, the future fair market value of Class A common stock, and future hiring and retention needs, all of which are difficult to predict and subject to constant change.

Conference Call and Webcast Information

StubHub will host a conference call and live webcast to discuss its third quarter 2026 results today at 5:00 PM Eastern Time.

The live webcast and replay may be accessed on StubHub’s investor relations website, investors.stubhub.com, along with a copy of the earnings presentation and this press release.

About StubHub

StubHub is a leading global ticketing marketplace for live events. Through StubHub and its international brand viagogo, the company services customers in over 200 countries and territories, supporting over 30 languages and accepting payments in over 45 currencies – from sports to music, comedy to dance, festivals to theater. StubHub offers a safe and convenient way to buy or sell tickets to live events across the world for memorable live experiences.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial outlook for the full year 2026, growth in market position, growth strategies, and ability to deliver sustainable long-term value for our stakeholders. Our actual results may differ materially from expectations, and reported results should not be considered as an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, and you should not rely on these as predictions of future events. Factors that may cause differences include, without limitation: the demand for tickets on our platform or for live events in general; our ability to maintain relationships with buyers and sellers, including individual sellers, professional sellers and content rights holders; changes in or any limitation or discontinuation of support by internet search engines and related technologies that impact how consumers find information online; our ability to compete in the ticketing industry against current or future competitors; our ability to continue to improve our platform and maintain and enhance our brands; our ability to expand into adjacent market opportunities across live entertainment and into additional live event and experience categories; our ability to expand the adoption of our platform for open distribution and disrupt the legacy primary ticketing model; the effects of seasonal trends on our results of operations; our ability to attract and retain a qualified management team and other team members while controlling our labor costs; our ability to effectively manage our exposure to fluctuations in foreign currency exchange rates and rising inflation rates; our ability to comply with existing laws, rules and regulations as well as the implementation of new or changing laws, rules and regulations and other legal uncertainties; the impact of extraordinary events or adverse economic conditions on discretionary consumer and corporate spending or on the supply and demand of live events; our ability to successfully defend against litigation; our ability to maintain the integrity of our information systems and infrastructure, and to mitigate possible cybersecurity risks; our ability to generate sufficient cash flows or raise additional capital necessary to fund our operations or service our debt, contractual commitments or obligations; our ability to remediate material weaknesses in our internal control over financial reporting; and the increased expenses associated with being a public company. For additional information on other potential risks and uncertainties that could cause actual results to differ from expected results, please refer to our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q. All forward-looking statements are based on information available to us as of the date of this press release and are made only as of such date. We undertake no obligation to update these statements to reflect subsequent events or circumstances, except as required by law.

STUBHUB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

(Unaudited)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2026

 

2025

 

2026

 

2025

Revenue

$

501,953

 

 

$

468,113

 

 

$

1,521,066

 

 

$

1,296,015

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of revenue (exclusive of depreciation and amortization shown separately below)

 

73,546

 

 

 

100,514

 

 

 

243,953

 

 

 

238,102

 

Operations and support

 

15,117

 

 

 

22,508

 

 

 

48,853

 

 

 

48,634

 

Sales and marketing

 

228,158

 

 

 

281,136

 

 

 

728,152

 

 

 

735,246

 

General and administrative

 

134,154

 

 

 

1,425,733

 

 

 

386,137

 

 

 

1,571,161

 

Depreciation and amortization

 

8,703

 

 

 

6,411

 

 

 

26,411

 

 

 

19,167

 

Total costs and expenses

 

459,678

 

 

 

1,836,302

 

 

 

1,433,506

 

 

 

2,612,310

 

Income (loss) from operations

 

42,275

 

 

 

(1,368,189

)

 

 

87,560

 

 

 

(1,316,295

)

Interest income

 

9,161

 

 

 

12,912

 

 

 

31,923

 

 

 

31,579

 

Interest expense

 

(21,502

)

 

 

(35,360

)

 

 

(60,970

)

 

 

(121,665

)

Other income, net

 

—

 

 

 

4,904

 

 

 

—

 

 

 

4,552

 

Foreign currency gains (losses)

 

2,460

 

 

 

(1,133

)

 

 

26,914

 

 

 

(86,303

)

Loss on extinguishment of debt

 

(1,804

)

 

 

(15,454

)

 

 

(3,681

)

 

 

(15,454

)

Gains on derivatives

 

760

 

 

 

1,471

 

 

 

7,050

 

 

 

637

 

Total other income (expense), net

 

(10,925

)

 

 

(32,660

)

 

 

1,236

 

 

 

(186,654

)

Income (loss) before income taxes

 

31,350

 

 

 

(1,400,849

)

 

 

88,796

 

 

 

(1,502,949

)

Benefit for income taxes

 

2,219

 

 

 

106,240

 

 

 

7,425

 

 

 

132,328

 

Net income (loss)

 

33,569

 

 

 

(1,294,609

)

 

 

96,221

 

 

 

(1,370,621

)

Net income (loss) attributable to common stockholders

$

18,561

 

 

$

(1,331,317

)

 

$

51,058

 

 

$

(1,443,132

)

 

 

 

 

 

 

 

 

Net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

Basic

$

0.05

 

 

$

(4.27

)

 

$

0.14

 

 

$

(4.70

)

Diluted

$

0.05

 

 

$

(4.27

)

 

$

0.11

 

 

$

(4.71

)

 

 

 

 

 

 

 

 

Weighted-average shares used in computing net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

Basic

 

383,574,880

 

 

 

311,633,848

 

 

 

373,969,205

 

 

 

306,981,026

 

Diluted

 

388,353,318

 

 

 

312,956,375

 

 

 

384,022,801

 

 

 

307,421,868

 

STUBHUB HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

 

 

 

September 30,

 

December 31,

 

 

2026

 

2025

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

1,167,227

 

 

$

1,241,587

 

Accounts receivable

 

 

11,436

 

 

 

6,909

 

Inventory

 

 

1,716

 

 

 

9,228

 

Prepaid expenses and other current assets

 

 

79,895

 

 

 

37,924

 

Total current assets

 

 

1,260,274

 

 

 

1,295,648

 

Non-current assets:

 

 

 

 

Property and equipment, net

 

 

143,189

 

 

 

73,254

 

Trademarks and trade names

 

 

864,800

 

 

 

864,800

 

Other intangible assets, net

 

 

23,419

 

 

 

38,243

 

Goodwill

 

 

2,686,701

 

 

 

2,686,701

 

Restricted cash

 

 

12,878

 

 

 

17,543

 

Deferred tax assets

 

 

2,060

 

 

 

2,083

 

Other non-current assets

 

 

54,680

 

 

 

75,781

 

Total assets

 

$

5,048,001

 

 

$

5,054,053

 

Liabilities, Redeemable Preferred Stock, and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

85,853

 

 

$

71,087

 

Payments due to buyers and sellers

 

 

860,735

 

 

 

845,892

 

Accrued expenses and other current liabilities (including zero and $17,894 under the fair value option, respectively)

 

 

362,812

 

 

 

334,305

 

Total current liabilities

 

 

1,309,400

 

 

 

1,251,284

 

Non-current liabilities:

 

 

 

 

Long-term debt obligations, non-current

 

 

1,297,585

 

 

 

1,506,957

 

Deferred tax liabilities

 

 

103,001

 

 

 

93,226

 

Other non-current liabilities

 

 

200,914

 

 

 

260,971

 

Total liabilities

 

 

2,910,900

 

 

 

3,112,438

 

Commitments and contingencies

 

 

 

 

Redeemable preferred stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 490,000 and 794,893 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively; aggregate liquidation preference of $736,149 and $1,027,583 as of September 30, 2026 and December 31, 2025, respectively

 

 

454,350

 

 

 

758,027

 

Stockholders’ equity:

 

 

 

 

Class A common stock, $0.001 par value; 3,000,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 357,434,430 and 321,320,641 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

 

 

357

 

 

 

321

 

Class B common stock, $0.001 par value; 200,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 24,750,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025

 

 

25

 

 

 

25

 

Additional paid-in capital

 

 

4,971,291

 

 

 

4,522,498

 

Accumulated other comprehensive income

 

 

25,460

 

 

 

71,347

 

Accumulated deficit

 

 

(3,314,382

)

 

 

(3,410,603

)

Total stockholders’ equity

 

 

1,682,751

 

 

 

1,183,588

 

Total liabilities, redeemable preferred stock, and stockholders’ equity

$

5,048,001

 

 

$

5,054,053

 

STUBHUB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

Nine Months Ended September 30,

 

2026

 

2025

Cash flows from operating activities:

 

 

 

Net income (loss)

$

96,221

 

 

$

(1,370,621

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

Depreciation

 

11,315

 

 

 

1,829

 

Amortization of intangible assets

 

15,096

 

 

 

17,338

 

Stock-based compensation

 

142,556

 

 

 

1,412,779

 

Amortization of debt issuance costs

 

3,728

 

 

 

6,535

 

Losses on derivatives

 

17,174

 

 

 

7,602

 

Amortization of unrealized losses on cash flow hedge

 

(23,893

)

 

 

(23,924

)

Unrealized foreign exchange (gains) losses

 

(29,010

)

 

 

87,647

 

Loss on extinguishment of debt

 

3,681

 

 

 

15,454

 

Deferred income taxes

 

(11,205

)

 

 

(135,458

)

Fair value change for preferred stocks and preferred stock bifurcated derivatives

 

(8,031

)

 

 

15,825

 

Other

 

1,702

 

 

 

6,840

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

(4,647

)

 

 

(491

)

Inventory

 

7,512

 

 

 

7,302

 

Prepaid expenses and other current assets

 

(24,703

)

 

 

(8,125

)

Other non-current assets

 

(3,080

)

 

 

(1,667

)

Operating lease right-of-use assets

 

3,501

 

 

 

3,359

 

Accounts payable

 

18,193

 

 

 

(49,937

)

Payments due to buyers and sellers

 

25,878

 

 

 

131,165

 

Accrued expenses and other current liabilities

 

(50,736

)

 

 

26,600

 

Other non-current liabilities

 

38,424

 

 

 

33,839

 

Operating lease liabilities

 

(8,179

)

 

 

(2,455

)

Net cash provided by operating activities

 

221,497

 

 

 

181,436

 

Cash flows from investing activities:

 

 

 

Capitalized software development costs

 

(30,462

)

 

 

(22,842

)

Purchases of property and equipment

 

(630

)

 

 

(1,170

)

Purchases of intangible assets

 

(271

)

 

 

(1,198

)

Net cash used in investing activities

 

(31,363

)

 

 

(25,210

)

Cash flows from financing activities:

 

 

 

Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions

 

—

 

 

 

758,000

 

Proceeds from issuance of Class A common stock upon exercise of stock options and warrants

 

190

 

 

 

59

 

Proceeds from issuance of Series N redeemable preferred stock

 

—

 

 

 

50,000

 

Proceeds from issuance of Series O redeemable preferred stock

 

—

 

 

 

254,893

 

Repurchase and retirement of Class A common stock

 

—

 

 

 

(1,000

)

Repayment of long-term debt obligations

 

(200,000

)

 

 

(759,763

)

Payments of tax withholding obligations on vested equity awards

 

(53,098

)

 

 

(81,607

)

Payments of deferred offering costs

 

(2,407

)

 

 

(10,050

)

Proceeds from partial interest rate swap termination

 

3,350

 

 

 

14,010

 

Net cash (used in) provided by financing activities

 

(251,965

)

 

 

224,542

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(2,798

)

 

 

12,723

 

Net (decrease) increase in cash, cash equivalents, and restricted cash

 

(64,629

)

 

 

393,491

 

Cash, cash equivalents, and restricted cash at beginning of period

 

1,259,130

 

 

 

1,015,912

 

Cash, cash equivalents, and restricted cash at end of period

$

1,194,501

 

 

$

1,409,403

 

STUBHUB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – continued

(In thousands)

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

2026

 

2025

Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets:

 

 

 

 

Cash and cash equivalents

 

$

1,167,227

 

$

1,392,458

Restricted cash in prepaid expenses and other current assets

 

 

14,396

 

 

352

Restricted cash

 

 

12,878

 

 

16,593

Total cash, cash equivalents, and restricted cash

 

$

1,194,501

 

$

1,409,403

Supplemental cash flow information

 

 

 

 

Cash paid for:

 

 

 

 

Interest

 

$

88,730

 

$

159,442

Non-cash investing and financing activities:

 

 

 

 

Stock-based compensation capitalized in development of capitalized software

 

$

47,771

 

$

28,342

Deferred offering costs accrued, unpaid

 

$

—

 

$

4,335

Key Business Metric and Non-GAAP Financial Measures

StubHub regularly reviews the key business metric, GMS, and the non-GAAP financial measures, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Net Leverage, Adjusted Gross Margin, Adjusted Sales and Marketing Expenses, Adjusted Operations and Support Expenses, and Adjusted General and Administrative Expenses to evaluate our business, measure our performance, identify trends, prepare financial projections and make business decisions. The measures set forth below should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these measures differently or not at all, which reduces their usefulness as comparative measures. A reconciliation of the non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP is set forth below under “Reconciliations of GAAP to Non-GAAP Financial Measures.” A reconciliation of our Adjusted EBITDA guidance to the corresponding GAAP measure is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to our results computed in accordance with GAAP. For example, stock-based compensation-related charges are impacted by the timing of employee stock transactions, the future fair market value of our Class A common stock, and our future hiring and retention needs, all of which are difficult to predict and subject to constant change.

Gross Merchandise Sales represents the total dollar value paid by buyers for ticket transactions and fulfillment. GMS includes fees we charge buyers and sellers that can vary by transaction, as well as the net proceeds we remit to sellers. Our definition of GMS does not include applicable sales, value-added and other indirect taxes, shipping costs and the impact of discounts and coupons as well as event cancellations or expected cancellations after the initial transaction on our platform. We believe it is useful to exclude these items, primarily refunds due to event cancellations, as GMS is a key metric used by management to measure business performance.

Adjusted EBITDA is calculated as net income (loss) excluding results from non-operating sources including interest income and expense, (benefit) provision for income taxes, other (income) expense, net, foreign currency (gains) losses, (gains) losses on derivatives, depreciation and amortization, acquisition-related costs, loss on extinguishment of debt, stock-based compensation expense, indirect tax contingency costs, litigation reserves and other costs and expenses. Adjusted EBITDA is a key performance measure that our management team uses to assess our operating performance. We present Adjusted EBITDA because management believes it is helpful in highlighting trends in our operating results as it excludes certain items, such as stock-based compensation expense, which are non-cash or whose fluctuations from period-to-period do not necessarily correspond to changes in the operating results of our business. Moreover, it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry.

Adjusted EBITDA has limitations as an analytical measure and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. In addition, other companies, including companies in our industry, may calculate Adjusted EBITDA differently, which reduces its usefulness as a comparative measure. Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including various cash flow metrics, net income (loss) and other GAAP results.

Free Cash Flow is defined as net cash (used in) provided by operating activities less capital expenditures, which includes purchases of property and equipment, purchases of intangible assets and capitalized software development costs (excluding capitalized stock-based compensation expense). We believe that Free Cash Flow is a meaningful indicator of liquidity for management and investors and, in particular, the amount of cash generated from operations that, after capital expenditures, can be used for strategic initiatives, including continuous investment in our business and strengthening our balance sheet. A limitation of the use of Free Cash Flow is that it does not represent the total increase or decrease in our cash balance for the period. Free Cash Flow should not be considered in isolation or as an alternative to cash flows from operations and should be considered alongside our other financial liquidity measures, such as net cash (used in) provided by operating activities and our other GAAP results.

Net Leverage is defined as (a) total debt, less cash and cash equivalents plus payments due to sellers divided by (b) trailing 12-month Adjusted EBITDA. We believe that Net Leverage provides investors a more complete understanding of our leverage position and borrowing capacity after factoring in cash and cash equivalents that eventually could be used to repay outstanding debt.

Adjusted Gross Margin is defined as (a) revenue less Adjusted Cost of Revenue (which is cost of revenue excluding stock-based compensation expense) divided by (b) revenue. We present Adjusted Gross Margin because management believes it is helpful in highlighting trends in our operating results as it excludes stock-based compensation expense, which is a non-cash expense.

Adjusted Sales and Marketing Expenses is defined as sales and marketing expenses excluding stock-based compensation expense. We present Adjusted Sales and Marketing Expenses because management believes it is helpful in highlighting trends in our expense management as it excludes stock-based compensation expense, which is a non-cash expense.

Adjusted Operations and Support Expenses is defined as operations and support expenses excluding stock-based compensation expense. We present Adjusted Operations and Support Expenses because management believes it is helpful in highlighting trends in our expense management as it excludes stock-based compensation expense, which is a non-cash expense.

Adjusted General and Administrative Expenses is defined as general and administrative expenses excluding stock-based compensation expense, acquisition-related costs, indirect tax contingency costs, litigation reserves and other costs and expenses that we do not consider to be representative of the ongoing financial performance of our core business. We present Adjusted General and Administrative Expenses because management believes it is helpful in highlighting trends in our expense management as it excludes certain items, such as stock-based compensation expense, which are non-cash or whose fluctuations from period-to-period do not necessarily correspond to changes in the operating results of our business.

STUBHUB HOLDINGS, INC.

RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES

(In thousands, except percentages)

(Unaudited)

 

Adjusted EBITDA

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

Net income (loss)

 

$

33,569

 

 

$

(1,294,609

)

 

$

96,221

 

 

$

(1,370,621

)

Add (deduct):

 

 

 

 

 

 

 

 

Interest income

 

 

(9,161

)

 

 

(12,912

)

 

 

(31,923

)

 

 

(31,579

)

Interest expense

 

 

21,502

 

 

 

35,360

 

 

 

60,970

 

 

 

121,665

 

Benefit for income taxes

 

 

(2,219

)

 

 

(106,240

)

 

 

(7,425

)

 

 

(132,328

)

Other income, net

 

 

—

 

 

 

(4,904

)

 

 

—

 

 

 

(4,552

)

Foreign currency (gains) losses

 

 

(2,460

)

 

 

1,133

 

 

 

(26,914

)

 

 

86,303

 

Gains on derivatives

 

 

(760

)

 

 

(1,471

)

 

 

(7,050

)

 

 

(637

)

Depreciation and amortization

 

 

8,703

 

 

 

6,411

 

 

 

26,411

 

 

 

19,167

 

Loss on extinguishment of debt

 

 

1,804

 

 

 

15,454

 

 

 

3,681

 

 

 

15,454

 

Acquisition-related costs(1)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

250

 

Stock-based compensation expense(2)

 

 

42,542

 

 

 

1,405,248

 

 

 

142,556

 

 

 

1,412,779

 

Indirect tax contingency costs(3)

 

 

11,465

 

 

 

12,992

 

 

 

17,938

 

 

 

34,938

 

Litigation reserves(4)

 

 

19,016

 

 

 

7,000

 

 

 

26,887

 

 

 

7,000

 

Other costs and expenses(5)

 

 

75

 

 

 

4,031

 

 

 

466

 

 

 

11,942

 

Adjusted EBITDA

 

$

124,076

 

 

$

67,493

 

 

$

301,818

 

 

$

169,781

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

501,953

 

 

$

468,113

 

 

$

1,521,066

 

 

$

1,296,015

 

Net income (loss) as a percentage of revenue

 

 

7

%

 

 

(277

)%

 

 

6

%

 

 

(106

)%

Adjusted EBITDA as a percentage of revenue

 

 

25

%

 

 

14

%

 

 

20

%

 

 

13

%

1.

 

During the nine months ended September 30, 2025, we incurred $0.3 million of transaction and integration costs. We do not consider these costs to be representative of the ongoing financial performance of our core business, and we do not expect these costs to be significant going forward.

2.

 

During the three months ended September 30, 2026 and 2025, we recognized $42.5 million and $1,405.2 million of stock-based compensation expense, net of $13.3 million and $28.2 million capitalized for internally developed software, associated with RSUs, stock options and restricted stock, respectively. During the nine months ended September 30, 2026 and 2025, we recognized $142.6 million and $1,412.8 million of stock-based compensation expense, net of $47.8 million and $28.3 million capitalized for internally developed software, associated with RSUs, stock options and restricted stock, respectively.

3.

 

During the three months ended September 30, 2026 and 2025, we incurred $4.5 million and $12.8 million of expenses, respectively, associated with potential indirect tax contingencies for withholding obligations and $7.0 million and $0.2 million of professional service costs, respectively. During the nine months ended September 30, 2026 and 2025, we incurred $10.5 million and $33.7 million of expenses, respectively, associated with potential indirect tax contingencies for withholding obligations and $7.4 million and $1.3 million of professional service costs, respectively.

4.

 

During the three months ended September 30, 2026 and 2025, we incurred $19.0 million and $7.0 million, respectively, and during the nine months ended September 30, 2026 and 2025, we incurred $26.9 million and $7.0 million, respectively, for expenses due to a litigation-related loss contingency for specific matters for which we deemed loss to be probable as described in Note 12, “Commitments and Contingencies” to our interim condensed consolidated financial statements.

5.

 

Represents (a) a one-time expense related to our initial public offering of $0.1 million and $4.0 million for the three months ended September 30, 2026 and 2025, respectively, and $0.5 million and $4.0 million for the nine months ended September 30, 2026 and 2025, respectively, (b) a one-time expense to terminate an intellectual property rights licensing agreement of $7.7 million for the nine months ended September 30, 2025 and (c) personnel-related costs related to our customer service office closure of $0.2 million for the nine months ended September 30, 2025. We do not consider these expenses to be representative of the ongoing financial performance of our core business.

Free Cash Flow

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

 

(in thousands)

Net cash (used in) provided by operating activities(1)

 

$

(398,778

)

 

$

3,795

 

 

$

221,497

 

 

$

181,436

 

Less: Capitalized software development costs

 

 

(11,048

)

 

 

(7,767

)

 

 

(30,462

)

 

 

(22,842

)

Less: Purchases of property and equipment

 

 

(45

)

 

 

(372

)

 

 

(630

)

 

 

(1,170

)

Less: Purchases of intangible assets

 

 

(227

)

 

 

(256

)

 

 

(271

)

 

 

(1,198

)

Free cash flow

 

$

(410,098

)

 

$

(4,600

)

 

$

190,134

 

 

$

156,226

 

TTM free cash flow(2)

 

$

192,097

 

 

$

5,601

 

 

 

 

 

1.

 

Includes $20.2 million and $39.6 million of interest payments on our outstanding debt, net of cash received on the settlement of interest rate swap derivatives, for the three months ended September 30, 2026 and 2025, respectively, and $64.5 million and $115.0 million for the nine months ended September 30, 2026 and 2025, respectively.

2.

 

Seasonal trends in our GMS and the timing of major events throughout the year, including the 2026 World Cup, impact free cash flow for any given quarter and can vary year to year. Trailing 12-month (“TTM”) free cash flow provides a longer-term view of our business that is less impacted by the seasonality of GMS and seller payments.

Reconciliation of Cost of Revenue to Adjusted Cost of Revenue

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

 

(in thousands)

Cost of revenue

 

$

73,546

 

 

$

100,514

 

 

$

243,953

 

 

$

238,102

 

Add (deduct):

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

(659

)

 

 

(23,356

)

 

 

(3,773

)

 

 

(23,356

)

Adjusted cost of revenue

 

$

72,887

 

 

$

77,158

 

 

$

240,180

 

 

$

214,746

 

Reconciliation of Operations and Support Expenses to Adjusted Operations and Support Expenses

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

 

(in thousands)

Operations and support

 

$

15,117

 

 

$

22,508

 

 

$

48,853

 

 

$

48,634

 

Add (deduct):

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

(74

)

 

 

(5,938

)

 

 

(533

)

 

 

(5,938

)

Adjusted operations and support

 

$

15,043

 

 

$

16,570

 

 

$

48,320

 

 

$

42,696

 

Reconciliation of Sales and Marketing Expenses to Adjusted Sales and Marketing Expenses

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

 

(in thousands)

Sales and marketing

 

$

228,158

 

 

$

281,136

 

 

$

728,152

 

 

$

735,246

 

Add (deduct):

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

(2,460

)

 

 

(26,462

)

 

 

(9,869

)

 

 

(26,462

)

Adjusted sales and marketing

 

$

225,698

 

 

$

254,674

 

 

$

718,283

 

 

$

708,784

 

Reconciliation of General and Administrative Expenses to Adjusted General and Administrative Expenses

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

 

(in thousands)

General and administrative

 

$

134,154

 

 

$

1,425,733

 

 

$

386,137

 

 

$

1,571,161

 

Add (deduct):

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

(39,349

)

 

 

(1,349,492

)

 

 

(128,381

)

 

 

(1,357,023

)

Litigation reserves

 

 

(19,016

)

 

 

(7,000

)

 

 

(26,887

)

 

 

(7,000

)

Indirect tax contingency costs

 

 

(11,465

)

 

 

(12,992

)

 

 

(17,938

)

 

 

(34,938

)

Acquisition-related costs

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(250

)

Other costs and expenses

 

 

(75

)

 

 

(4,031

)

 

 

(466

)

 

 

(11,942

)

Adjusted general and administrative

 

$

64,249

 

 

$

52,218

 

 

$

212,465

 

 

$

160,008

 

Reconciliation of Adjusted Gross Margin

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2026

 

2025

 

2026

 

2025

 

 

(in thousands)

Revenue

 

$

501,953

 

 

$

468,113

 

 

$

1,521,066

 

 

$

1,296,015

 

Cost of revenue

 

 

73,546

 

 

 

100,514

 

 

 

243,953

 

 

 

238,102

 

Stock-based compensation expense

 

 

(659

)

 

 

(23,356

)

 

 

(3,773

)

 

 

(23,356

)

Adjusted cost of revenue

 

 

72,887

 

 

 

77,158

 

 

 

240,180

 

 

 

214,746

 

Adjusted gross margin

 

$

429,066

 

 

$

390,955

 

 

$

1,280,886

 

 

$

1,081,269

 

Adjusted gross margin as a percentage of revenue

 

 

85

%

 

 

84

%

 

 

84

%

 

 

83

%

Reconciliation of Net Income (Loss) to TTM Adjusted EBITDA

 

 

Three Months Ended

 

 

September 30,

2026

 

June 30,

2026

 

March 31,

2026

 

December 31,

2025

 

September 30,

2025

 

June 30,

2025

 

March 31,

2025

 

December 31,

2024

 

 

(in thousands)

Net income (loss)

 

$

33,569

 

 

$

14,607

 

 

$

48,045

 

 

$

(535,313

)

 

$

(1,294,609

)

 

$

(53,829

)

 

$

(22,183

)

 

$

54,190

 

Add (deduct):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

(9,161

)

 

 

(12,236

)

 

 

(10,526

)

 

 

(10,833

)

 

 

(12,912

)

 

 

(10,365

)

 

 

(8,302

)

 

 

(9,832

)

Interest expense

 

 

21,502

 

 

 

22,200

 

 

 

17,268

 

 

 

18,370

 

 

 

35,360

 

 

 

43,868

 

 

 

42,437

 

 

 

45,209

 

(Benefit) provision for income taxes

 

 

(2,219

)

 

 

(2,375

)

 

 

(2,831

)

 

 

492,922

 

 

 

(106,240

)

 

 

(17,594

)

 

 

(8,494

)

 

 

30,469

 

Other (income) expense, net

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(4,904

)

 

 

352

 

 

 

—

 

 

 

—

 

Foreign currency (gains) losses

 

 

(2,460

)

 

 

(3,864

)

 

 

(20,590

)

 

 

3,361

 

 

 

1,133

 

 

 

61,125

 

 

 

24,045

 

 

 

(46,458

)

(Gains) losses on derivatives

 

 

(760

)

 

 

(753

)

 

 

(5,537

)

 

 

776

 

 

 

(1,471

)

 

 

1,499

 

 

 

(665

)

 

 

(721

)

Depreciation and amortization

 

 

8,703

 

 

 

9,815

 

 

 

7,893

 

 

 

6,437

 

 

 

6,411

 

 

 

6,412

 

 

 

6,344

 

 

 

6,393

 

Acquisition-related costs

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

125

 

 

 

125

 

 

 

125

 

Loss on extinguishment of debt

 

 

1,804

 

 

 

1,877

 

 

 

—

 

 

 

3,038

 

 

 

15,454

 

 

 

—

 

 

 

—

 

 

 

—

 

Stock-based compensation expense

 

 

42,542

 

 

 

69,008

 

 

 

31,006

 

 

 

34,889

 

 

 

1,405,248

 

 

 

2,037

 

 

 

5,494

 

 

 

3,381

 

Indirect tax contingency costs

 

 

11,465

 

 

 

3,888

 

 

 

2,585

 

 

 

18,566

 

 

 

12,992

 

 

 

12,981

 

 

 

8,965

 

 

 

14,094

 

Litigation reserves

 

 

19,016

 

 

 

3,378

 

 

 

4,493

 

 

 

30,080

 

 

 

7,000

 

 

 

—

 

 

 

—

 

 

 

5,727

 

Other costs and expenses

 

 

75

 

 

 

113

 

 

 

278

 

 

 

362

 

 

 

4,031

 

 

 

7,731

 

 

 

180

 

 

 

1,789

 

Adjusted EBITDA

 

$

124,076

 

 

$

105,658

 

 

$

72,084

 

 

$

62,655

 

 

$

67,493

 

 

$

54,342

 

 

$

47,946

 

 

$

104,366

 

TTM Adjusted EBITDA

 

$

364,473

 

 

$

307,890

 

 

$

256,574

 

 

$

232,436

 

 

$

274,147

 

 

 

 

 

 

 

Reconciliation of Net Cash (Used in) Provided by Operating Activities to TTM Free Cash Flow

 

 

Three Months Ended

 

 

September 30,

2026

 

June 30,

2026

 

March 31,

2026

 

December 31,

2025

 

September 30,

2025

 

June 30,

2025

 

March 31,

2025

 

December 31,

2024

 

 

(in thousands)

Net cash (used in) provided by operating activities

 

$

(398,778

)

 

$

321,859

 

 

$

298,416

 

 

$

11,133

 

 

$

3,795

 

 

$

19,320

 

 

$

158,321

 

 

$

(149,448

)

Less: Capitalized software development costs

 

 

(11,048

)

 

 

(11,785

)

 

 

(7,629

)

 

 

(8,690

)

 

 

(7,767

)

 

 

(8,846

)

 

 

(6,229

)

 

 

(521

)

Less: Purchases of property and equipment

 

 

(45

)

 

 

(416

)

 

 

(169

)

 

 

(223

)

 

 

(372

)

 

 

(291

)

 

 

(507

)

 

 

(340

)

Less: Purchases of intangible assets

 

 

(227

)

 

 

—

 

 

 

(44

)

 

 

(257

)

 

 

(256

)

 

 

(467

)

 

 

(475

)

 

 

(316

)

Free cash flow

 

$

(410,098

)

 

$

309,658

 

 

$

290,574

 

 

$

1,963

 

 

$

(4,600

)

 

$

9,716

 

 

$

151,110

 

 

$

(150,625

)

TTM cash flow provided by operations

 

$

232,630

 

 

$

635,203

 

 

$

332,664

 

 

$

192,569

 

 

$

31,988

 

 

 

 

 

 

 

TTM free cash flow

 

$

192,097

 

 

$

597,595

 

 

$

297,653

 

 

$

158,189

 

 

$

5,601

 

 

 

 

 

 

 

Net interest payment(1)

 

$

20,165

 

 

$

21,735

 

 

$

22,603

 

 

$

24,496

 

 

$

39,629

 

 

 

 

 

 

 

Change in payments due to buyers and sellers(2)

 

$

(446,613

)

 

$

198,842

 

 

$

273,649

 

 

$

(24,662

)

 

$

(29,555

)

 

 

 

 

 

 

1.

 

Includes interest payments on our outstanding debt, net of cash received on the settlement of interest rate swap derivatives.

2.

 

Includes change in payments due to buyers and sellers as noted in the condensed consolidated statements of cash flows.

Reconciliation of Net Leverage

 

 

September 30,

 

December 31,

 

 

2026

 

2025

 

 

(in thousands, except percentages)

2024 Euro Term Loan

 

$

513,816

 

 

$

531,041

 

2024 USD Term Loan

 

 

804,187

 

 

 

1,004,187

 

Principal amount—senior credit facilities

 

 

1,318,003

 

 

 

1,535,228

 

Add (deduct):

 

 

 

 

 

 

Cash and cash equivalents

 

 

(1,167,227

)

 

 

(1,241,587

)

Payments due to sellers(1)

 

 

750,685

 

 

 

747,363

 

Net Debt

 

$

901,461

 

 

$

1,041,004

 

TTM Adjusted EBITDA

 

$

364,473

 

 

$

232,436

 

Net Leverage

 

2.5 x

 

 

4.5 x

 

1.

 

Reported within payments due to buyers and sellers in notes to the condensed consolidated financial statements.

 

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software General Sports Sports Theatre Technology Events/Concerts Arts/Museums Entertainment

MEDIA:

Vivmark Residential Calls Series K Cumulative Redeemable Preferred Shares for Redemption

Vivmark Residential Calls Series K Cumulative Redeemable Preferred Shares for Redemption

ARLINGTON, Va. & CHICAGO–(BUSINESS WIRE)–
Vivmark Residential (NYSE: VMRK) (the “Company”) today announced that it has called for redemption, on December 10, 2026 (the “Redemption Date”), all of its outstanding Series K Cumulative Redeemable Preferred Shares of Beneficial Interest (the “Series K Preferred Shares”). The Series K Preferred Shares will be redeemed at a redemption price equal to their $50.00 per share liquidation preference, plus $0.806 per share in accrued and unpaid dividends from October 1, 2026 through the Redemption Date, for a total redemption price of $50.806 per share (the “Redemption Price”). As of the close of business on November 9, 2026, there were 343,100 Series K Preferred Shares outstanding with an aggregate liquidation preference of $17.155 million. From and after the Redemption Date, dividends on the Series K Preferred Shares will cease to accrue, the Series K Preferred Shares shall no longer be deemed outstanding and all rights of the holders of Series K Preferred Shares with respect to such shares will terminate, except the right to receive the Redemption Price, without interest.

A notice of redemption and related materials will be mailed to holders of record of the Series K Preferred Shares no later than November 16, 2026. Holders of the Series K Preferred Shares that hold their shares through The Depository Trust Company (“DTC”) will be redeemed in accordance with the applicable procedures of DTC. Questions relating to the notice of redemption and related materials should be directed to Computershare Trust Company, N.A., the Company’s transfer agent and the paying agent for the redemption of the Series K Preferred Shares (the “Paying Agent”), at 1-800-733-5001. The address of the Paying Agent is Computershare Trust Company, N.A., P.O. Box 43006, Providence, RI 02940-3006.

About Vivmark Residential

Vivmark Residential (NYSE: VMRK), a S&P 500 company, sets the mark for what home can be, and our vision is to be the most trusted and best-performing rental housing company in America, one that only gets better as it grows. Our people, scale and capabilities create a self-reinforcing performance cycle that is designed to deliver structurally higher growth. With more than 185,000 apartment homes across premier U.S. markets and $4.4 billion of active development, Vivmark is redefining what rental housing can be. For more details, please visit www.VivmarkResidential.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements, among other things, are based on current expectations, estimates and projections about the industry and markets in which Vivmark Residential (“Vivmark,” “we,” “us” or “our”) (f/k/a Equity Residential) operates, as well as beliefs and assumptions of Vivmark. Words such as “anticipate,” “become,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “target,” “seek,” “shall,” “should,” “will,” or “would,” including variations of such words and similar expressions, are intended to identify forward-looking statements. All statements that address operating performance, events or developments that Vivmark expects or anticipates will occur in the future are forward-looking statements, including statements relating to the anticipated synergies, cost savings and other benefits of the Merger (as defined below), integration plans, projected dividends, development net operating income, accretion and value creation, multifamily market conditions, development, redevelopment, acquisition or disposition activity, general conditions in the geographic areas where Vivmark operates and Vivmark’s debt, capital structure and financial position. Such forward-looking statements are based on the current expectations of our management, are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other factors that are difficult to predict and may cause the actual results to differ materially from future results expressed or implied by such forward-looking statements.

Important factors, risks and uncertainties that could cause actual results to differ materially from such plans, estimates or expectations include but are not limited to: the inability to realize the anticipated benefits of the merger (the “Merger”) between AvalonBay Communities, Inc. (“AvalonBay”) and Equity Residential (which Merger formed Vivmark), including as a result of an integration of the two businesses that is unsuccessful or that is more difficult, time-consuming or costly than expected; unknown or inestimable liabilities that arise as a result of the Merger; potential litigation relating to the Merger that could be instituted against Vivmark or its trustees or officers; the risk that disruptions related to post-Merger integration and other efforts will harm Vivmark’s business; increased costs of labor and construction material; potential failure to secure development opportunities due to an inability to reach agreements with third parties to obtain land at attractive prices or to obtain desired zoning and other local approvals; abandonment or deferment of development opportunities for a number of reasons, including changes in local market conditions, increases in costs of development, increases in the cost of capital or lack of capital availability, resulting in losses; construction costs of a community may exceed original estimates; inability to complete construction and lease-up of communities under development or redevelopment on schedule, resulting in increased interest costs and construction costs and a decrease in expected rental revenues; occupancy rates and market rents being adversely affected by competition and local economic and market conditions which are beyond our control; geopolitical conditions and instability, and international trade disputes, including any related tariffs, which may lead to rising inflation, adverse impacts to supply chains, and disruption of, or lack of access to, the capital markets, as well as potential volatility in Vivmark’s share price; our cash flows from operations and access to cost-effective capital potentially being insufficient for the development of our pipeline, which could limit our pursuit of opportunities; our cash flows potentially being insufficient to meet required payments of principal and interest, and inability to refinance existing indebtedness or the terms of such refinancing may not be as favorable as the terms of existing indebtedness; new or existing laws and regulations that adversely impact the markets in which we operate or our business, including those relating to rent control or rent stabilization, or that otherwise limit our ability to increase rents, charge non-rent fees or evict tenants, which may impact our revenue or increase our costs; risks related to our reliance on information technology systems, data and artificial intelligence or other automated tools, including cybersecurity incidents and other privacy or data security events, evolving regulation of the collection and use of resident data and of automated or algorithmic tools, and the failure of such systems or tools to perform as intended; and investments made under our structured investment program may not be repaid as expected or the development may not be completed on schedule, which could require us to engage in litigation, foreclosure actions, and/or first party project completion to recover our investment, which may not be recovered in full or at all in such event; and those risks and uncertainties set forth in Equity Residential’s and AvalonBay’s respective Annual Reports on Form 10-K for the year ended December 31, 2025 under the headings “Forward-Looking Statements” and “Risk Factors,” as such risk factors were amended, supplemented or superseded from time to time by subsequent reports filed by Equity Residential and AvalonBay, respectively, including those risks described under “Risk Factors” in the definitive joint proxy statement/prospectus of Equity Residential and AvalonBay, dated July 13, 2026, and which may be further amended, supplemented or superseded from time to time by Vivmark’s subsequent filings with the Securities and Exchange Commission (the “SEC”), in each case which are available via the SEC’s website at www.sec.gov.

These factors should not be construed as exhaustive and should be read in conjunction with the other forward-looking statements. Forward-looking statements relate only to events as of the date on which the statements are made. Vivmark does not undertake any obligation to publicly update or revise any forward-looking statement except as required by law, whether as a result of new information, future developments or otherwise. Vivmark cautions not to place undue reliance on any of Vivmark’s forward-looking statements. Furthermore, new risks and uncertainties arise from time to time, and it is impossible for us to predict those events or how they may affect Vivmark.

Investor Contacts

Marty McKenna

[email protected]

Matthew Grover, CFA

[email protected]

KEYWORDS: Illinois Virginia United States North America

INDUSTRY KEYWORDS: Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Core & Main Announces Preliminary Third-Quarter Fiscal 2026 Results, Updated Fiscal 2026 Outlook, Multiple Acquisitions and Record Share Repurchases

Core & Main Announces Preliminary Third-Quarter Fiscal 2026 Results, Updated Fiscal 2026 Outlook, Multiple Acquisitions and Record Share Repurchases

  • Preliminary third quarter net sales of $2.12 billion to $2.13 billion, net income of $128 million to $140 million and Adjusted EBITDA (Non-GAAP) of $267 million to $275 million

  • Maintains fiscal 2026 net sales outlook and updates Adjusted EBITDA (Non-GAAP) outlook to $950 million to $960 million, from $950 million to $980 million

  • Completes three acquisitions with over $250 million in combined annual revenue

  • Repurchases a quarterly record $171 million of shares

ST. LOUIS–(BUSINESS WIRE)–Core & Main, Inc. (NYSE: CNM) (“Core & Main” or the “Company”), a leading specialty distributor dedicated to advancing reliable infrastructure with local service, nationwide, today announced, in advance of its participation at the 2026 Baird Global Industrial Conference, preliminary estimated financial results for the third quarter ended November 1, 2026, an updated fiscal 2026 outlook, its third consecutive quarter of record open-market share repurchases and the completion of three acquisitions. The Company expects to report full third quarter fiscal 2026 results on December 8, 2026.

Unaudited Preliminary Estimated Results for the Third Quarter Ended November 1, 2026

Set forth below are unaudited preliminary estimated financial results for the Company for the third quarter of fiscal 2026, based on information available as of the date of this press release. This summary is not a comprehensive statement of our financial results for the quarterly period. The amounts are preliminary estimates and are subject to revision based on completion of the Company’s quarter-end financial closing process, final review by management, the related external review of the Company’s results of operations and the preparation of full financial statements and related notes. While we expect that our final financial results for the third quarter of fiscal 2026, following the completion of our quarter-end financial closing procedures, will be within the ranges described above, our actual results may differ materially from these estimates as a result of the completion of such closing procedures as well as final adjustments and other developments that may arise between now and the time that our financial results for this quarterly period are finalized.

The preliminary financial information included in this news release has been prepared by, and is the responsibility of the Company. PricewaterhouseCoopers LLP, an independent registered public accounting firm and the Company’s auditor, has not audited, reviewed, examined, compiled nor applied agreed-upon procedures with respect to the preliminary financial information. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The processes used to produce the preliminary financial information required a greater degree of estimation and assumptions than a typical period-end closing process. This preliminary information should not be considered a substitute for financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), and investors should not place undue reliance on it.

The preliminary estimates are not necessarily indicative of results for any future period or the full fiscal year and should be read together with the Company’s filings with the Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to update or revise the preliminary estimates.

 

Three Months Ended

 

November 1, 2026

(low end of the range)

 

November 1, 2026

(high end of the range)

 

November 2, 2025

 

Dollars in millions, unaudited

Net sales

$

2,120

 

$

2,130

 

$

2,062

Net income

$

128

 

$

140

 

$

143

Adjusted EBITDA(1)

$

267

 

$

275

 

$

274

 

(1) Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” below for the definition and reconciliation to net income, the most directly comparable GAAP measure.

Preliminary Third Quarter Results and Updated Fiscal 2026 Outlook

In the third quarter, Core & Main delivered 3% sales growth amid a mixed demand environment. Preliminary Adjusted EBITDA (Non-GAAP) was affected by higher transportation costs and investments in greenfields to drive long-term growth. Based on these preliminary results and current expectations for the remainder of the fiscal year, the Company maintains its fiscal 2026 net sales outlook of $7.8 billion to $7.9 billion and now expects fiscal 2026 Adjusted EBITDA (Non-GAAP) of $950 million to $960 million. The updated outlook continues to reflect stable municipal demand along with contributions from completed acquisitions, partially offset by softer-than-anticipated residential lot development and light commercial activity.

“We continue to execute our strategy across multiple avenues for growth, strengthening our platform through acquisitions in storm drainage, fusible HDPE and smart utility solutions and completing another record quarter of open market share repurchases,” said Mark Witkowski, Chief Executive Officer of Core & Main. “We also continue to invest organically in our business, opening a record eight greenfield locations year to date. We remain confident in our strategy and focused on the opportunities ahead as we continue to position Core & Main for long-term growth and value creation.”

Acquisitions and Share Repurchases

Core & Main completed the following acquisitions, representing over $250 million in combined annual revenue:

  • In September, Core & Main acquired Southwest Stormwater Solutions, which operates from one location in Phoenix, Arizona. Southwest Stormwater Solutions is a provider of proprietary underground stormwater vault systems for municipalities, contractors and civil engineers,

  • In October, Core & Main acquired Gajeske, LLC (“Gajeske”), based in Houston, Texas. Gajeske is a leading distributor of fusible HDPE pipe and fittings with deep technical expertise, providing fabrication, equipment rental and other value-added services from eight locations across Texas and Oklahoma; and

  • In November, Core & Main acquired KTI Limited and KTI Utility Services (collectively, “KTI”), based in Toronto, Canada. KTI is a distributor and utility solutions provider, offering comprehensive, turnkey meter and AMI solutions, including installation and related field services from seven locations across Ontario and Alberta.

In addition, Core & Main repurchased a record $171 million of shares in the open market during the third quarter of fiscal 2026, bringing year-to-date repurchases to approximately $428 million, with approximately $240 million remaining under its current share repurchase authorization.

Non-GAAP Financial Measures

In addition to providing results that are determined in accordance with GAAP, the Company presents Adjusted EBITDA, which is a non-GAAP financial measure. This measure is not considered a measure of financial performance or liquidity under GAAP, and the items excluded therefrom are significant components in understanding and assessing the Company’s financial performance or liquidity. This measure should not be considered in isolation or as alternatives to GAAP measures such as net income, cash provided by or used in operating, investing or financing activities or other financial statement data presented in the Company’s financial statements as an indicator of the Company’s financial performance or liquidity.

The Company defines EBITDA as net income adjusted for depreciation and amortization, provision for income taxes and interest expense. The Company defines Adjusted EBITDA as EBITDA as further adjusted for certain items management believes are not reflective of the underlying operations of the Company’s business, including but not limited to (a) loss on debt modification and extinguishment, (b) equity-based compensation, (c) expenses associated with the initial public offering and subsequent secondary offerings and (d) other income or other expense. Net income attributable to Core & Main, Inc. is the most directly comparable GAAP measure to Adjusted EBITDA.

The Company uses Adjusted EBITDA to assess the operating results and effectiveness and efficiency of its business. The Company presents this non-GAAP financial measure because it believes that investors consider it to be an important supplemental measure of performance, and it believes that this measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in its industry. Non-GAAP financial measures as reported by the Company may not be comparable to similarly titled metrics reported by other companies and may not be calculated in the same manner. These measures have limitations as analytical tools, and you should not consider them in isolation or as substitutes for analysis of the Company’s results as reported under GAAP. For example, Adjusted EBITDA:

  • does not reflect the significant interest expense or the cash requirements necessary to service interest or principal payments on debt;

  • does not reflect income tax expenses, the cash requirements to pay taxes or related distributions;

  • does not reflect cash requirements to replace in the future any assets being depreciated and amortized; and

  • excludes certain transactions or expenses as allowed by the various agreements governing our indebtedness.

Adjusted EBITDA is not an alternative measure of financial performance or liquidity under GAAP and therefore should be considered in conjunction with net income and other performance measures such as gross profit or net cash provided by or used in operating, investing or financing activities and not as alternatives to such GAAP measures. In evaluating Adjusted EBITDA, you should be aware that, in the future, the Company may incur expenses similar to those eliminated in this presentation.

The following table sets forth a reconciliation of net income to Adjusted EBITDA for the periods presented.

 

Three Months Ended

 

November 1, 2026

(low end of the range)

 

November 1, 2026

(high end of the range)

 

November 2, 2025

 

Dollars in millions, unaudited

Net income

$

128

 

$

140

 

$

143

Depreciation and amortization(1)

 

46

 

 

46

 

 

47

Provision for income taxes

 

42

 

 

38

 

 

47

Interest expense

 

39

 

 

39

 

 

30

EBITDA

$

255

 

$

263

 

$

267

Equity-based compensation

 

3

 

 

3

 

 

4

Other expenses(2)

 

9

 

 

9

 

 

3

Adjusted EBITDA

$

267

 

$

275

 

$

274

(1)

Includes depreciation of certain assets which are reflected in “cost of sales” in our Statement of Operations.

 

(2)

Represents expenses associated with acquisition and other activities, including transaction costs, contingent consideration arrangement fair value adjustments, post-acquisition employee retention bonuses, severance payments and expense recognition of purchase accounting fair value adjustments (excluding amortization).

No reconciliation of the estimated range for Adjusted EBITDA for fiscal 2026 is included herein because we are unable to quantify certain amounts that would be required to be included in net income attributable to Core & Main, Inc., without unreasonable efforts due to the high variability and difficulty to predict certain items excluded from Adjusted EBITDA. Consequently, we believe such reconciliation would imply a degree of precision that would be misleading to investors. In particular, the effects of acquisition expenses cannot be reasonably predicted in light of the inherent difficulty in quantifying such items on a forward-looking basis. We expect the variability of these excluded items may have an unpredictable, and potentially significant, impact on our future GAAP financial results.

About Core & Main

Based in St. Louis, Core & Main is a leader in advancing reliable infrastructure® with local service, nationwide®. As a specialty distributor with a focus on water, wastewater, storm drainage and fire protection products and related services, Core & Main provides solutions to municipalities, private water companies and professional contractors across municipal, non-residential and residential end markets in the United States and Canada. With more than 370 locations, the Company provides its customers local expertise backed by a national supply chain. Core & Main’s 5,600 associates are committed to helping their communities thrive with safe and reliable infrastructure. Visit coreandmain.com to learn more.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, all statements other than statements of historical or current facts contained in this press release, including statements relating to our intentions, beliefs, assumptions or current expectations concerning, among other things, our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding expected growth, future capital expenditures, capital allocation and debt service obligations, and the anticipated impact on our business.

Some of the forward-looking statements can be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,” “seeks,” “aims,” “projects,” “is optimistic,” “intends,” “plans,” “estimates,” “anticipates” or the negative versions of these words or other comparable terms. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be outside our control. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of the market in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if our results of operations, financial condition, cash flows and the development of the market in which we operate are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. A number of important factors, including, without limitation, the risks and uncertainties discussed under the captions “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended February 1, 2026 and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended February 1, 2026, could cause actual results and outcomes to differ materially from those reflected in the forward-looking statements. Furthermore, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release.

Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements include, without limitation, declines, volatility and cyclicality in the U.S. residential and non-residential construction markets; slowdowns in municipal infrastructure spending and delays in appropriations of federal funds; our ability to competitively bid for contracts; price fluctuations in our product costs (including effects of tariffs); our ability to manage our inventory effectively, including during periods of supply chain disruptions; risks involved with acquisitions and other strategic transactions, including our ability to identify, acquire, close or integrate acquisition targets successfully; the fragmented and highly competitive markets in which we compete and consolidation within our industry; the development of alternatives to distributors of our products in the supply chain; our ability to hire, engage and retain key personnel, including sales representatives, qualified branch, district and regional managers and senior management; our ability to identify, develop and maintain relationships with a sufficient number of qualified suppliers and the potential that our exclusive or limited supplier distribution rights are terminated; changes in supplier rebates or other terms of our supplier agreements; the availability of freight; the ability of our customers to make payments on credit sales; our ability to identify and introduce new products and product lines effectively; the spread of, and response to, public health crises and the inability to predict the ultimate impact on us; costs and potential liabilities or obligations imposed by environmental, health and safety laws and requirements; regulatory change and the costs of compliance with regulation; changes in stakeholder expectations in respect of environmental, social and governance and sustainability practices; exposure to product liability, construction defect and warranty claims and other litigation and legal proceedings; potential harm to our brand or reputation; difficulties with or interruptions of our fabrication services; safety and labor risks associated with the distribution of our products; interruptions in the proper functioning of our and our third-party service providers’ information technology systems, including from cybersecurity threats; impairment in the carrying value of goodwill, intangible assets or other long-lived assets; our ability to continue our customer relationships with short-term contracts; risks associated with operating internationally, including exporting and importing of certain products; our indebtedness and the potential that we may incur additional indebtedness that might restrict our operating flexibility; the limitations and restrictions in the agreements governing our indebtedness, the Amended and Restated Limited Partnership Agreement of Core & Main Holdings, LP, as amended, and the Tax Receivable Agreements (each as defined in our Annual Report on Form 10-K for the fiscal year ended February 1, 2026); increases in interest rates on our variable rate indebtedness; changes in our credit ratings and outlook; our ability to generate the significant amount of cash needed to service our indebtedness; our organizational structure, including our payment obligations under the Tax Receivable Agreements, which may be significant; our ability to sustain an active, liquid trading market for our Class A common stock; and risks related to other factors discussed under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended February 1, 2026.

Additional information concerning these and other factors can be found in our filings with the Securities and Exchange Commission. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Relations:

Landon Althoff, 314-372-0264

[email protected]

Media Relations:

Patrick Lunsford, 314-789-0726

[email protected]

KEYWORDS: Missouri United States North America

INDUSTRY KEYWORDS: Engineering Other Energy Manufacturing Residential Building & Real Estate Energy Commercial Building & Real Estate Construction & Property Transport Building Systems Other Natural Resources Natural Resources Urban Planning Other Manufacturing Logistics/Supply Chain Management

MEDIA:

Logo
Logo

Firefly Aerospace Announces Third Quarter 2026 Financial Results With Record Backlog of $1.7 Billion

Completed cleanroom expansion to scale Moon Base spacecraft production, signed first European launch contracts, while ramping up Alpha Block II manufacturing and executing across multiple national security programs of record.

A Miranda engine test firing in September 2026 at Firefly’s Rocket Ranch in Briggs, Texas.
Credit: Firefly Aerospace

CEDAR PARK, Texas, Nov. 10, 2026 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, today issued financial results for the third quarter ended September 30, 2026.

“Firefly’s third quarter reflects the power of our diversified and vertically-integrated business,” said Jason Kim, CEO of Firefly Aerospace. “With five Moon missions running in parallel, Alpha Block II moving toward launch, SciTec executing on critical national security programs, and our strategic deal with AST SpaceMobile, we are converting our pipeline and backlog into results.”

Third Quarter 2026 Highlights

  • Revenue of $110.7 million, up 259% from the same period a year prior.
  • Record backlog of $1.7 billion at quarter end, up from $1.5 billion at the end of the prior quarter.
  • Completed expansion and began operating in the Company’s spacecraft cleanroom facility, funded through a non-dilutive Texas Space Commission grant, which enables simultaneous assembly and integration of up to 12 lunar landers and orbital vehicles.
  • Awarded Firefly’s first Mars award, with a $13 million subcontract to support the SkyFall mission for NASA JPL, to manufacture, test, and deliver the aeroshell ahead of launch targeted for late 2028.
  • Signed an extension to Lockheed Martin’s multi-launch agreement for up to 25 Alpha launches through 2031 using the Block II configuration.
  • Signed with SSC Space for two commercial Alpha launches from Esrange Space Center in Sweden, representing Firefly’s first European launch contracts.
  • Awarded a $94 million Space Force contract under the Ground-Based Radar Digitization program, to support work overhauling legacy defense systems.
  • Onboarded to the $981 million Space Force IDIQ contract for NITE-STAR – the National Space Test and Training Complex Innovative Technology and Engineering – Space Test and Range Capability Development, to compete for task orders to support advanced test and training operations through 2032.
  • Awarded a contract from the Defense Innovation Unit to design an Elytra deorbit system, expanding the Elytra mission portfolio into active debris removal and responsible end-of-life orbital services.
  • Onboarded to NASA’s Spacecraft Processing Operations Contract (SPOC), expanding Firefly’s formal partnership with NASA to provide spacecraft processing and operational support services.
  • Signed a commercial partnership with Starcloud to demonstrate advanced AI compute in lunar orbit, marking Firefly’s first commercial customer for data center capabilities around the Moon.
  • Added Zeno Power Systems as a commercial payload customer for the accelerated Blue Ghost mission to the Moon’s near side, to deliver a Survive-the-Night Package with a Radioisotope Heater Unit (RHU).

Additional Recent Highlights

  • Signed contracts valued at more than $1.3 billion with AST SpaceMobile, which includes licensed IP, engine delivery, and engineering support.
  • Onboarded as a vendor to NASA’s $10 billion CLPS 2 initiative, to compete for and deliver task orders for large cargo landers to deliver critical infrastructure needed for the agency’s Moon Base.
  • Signed Japanese synthetic aperture radar satellite company Synspective to a multi-launch agreement for up to 10 Alpha launches through 2030.
  • Began Miranda engine qualification campaign, with more than 170 hot fire tests completed to date, a key step toward the first Eclipse launch.
  • Extended the U.S. Air Force contract for SciTec’s work on Cloud-Based Command and Control (CBC2) to integrate a new class of counter unmanned aerial system (CUAS) sensor feeds for the Advanced Battle Management System.
  • Completed the MoonFall Preliminary Design Review, verifying the Elytra spacecraft’s design to support the flagship NASA mission to the Moon’s south pole.
  • Achieved a FORGE operational milestone for the U.S. Space Force system developed by SciTec, incorporating data from the Space Systems Command’s Wide Field of View space vehicle in geostationary Earth orbit (GEO) and expanding the system’s observational reach to strengthen missile warning and defense.
  • Completed the critical design review for Blue Ghost’s mission to the South Pole, progressing development of the spacecraft for the NASA flight.
  • Awarded a third hypersonic task order for Alpha from a confidential customer.

2026 Full-Year Guidance

  • Firefly expects 2026 full-year revenue to be between $440 million and $450 million.

Conference Call

Firefly will host a conference call today at 4:00 p.m. CT (5:00 p.m. ET) to discuss its third quarter 2026 financial results.

The live webcast and accompanying presentation, as well as a replay of the webcast, will be available on Firefly’s Investor Relations website: investors.fireflyspace.com.

About Firefly Aerospace

Firefly Aerospace is a space and defense technology company on a mission to reliably and repeatedly launch, land, and operate space systems from Earth to the Moon and beyond. As the partner of choice for responsive space missions, Firefly is the first commercial company to launch a satellite to orbit with approximately 24-hour notice and the first to achieve a successful Moon landing. Firefly’s launch, lunar, and orbital vehicles paired with its AI software and data processing capabilities support end-to-end missions across cislunar space, including payload delivery and maneuverability, space domain awareness, and missile warning and tracking. Established in 2017, Firefly’s engineering, manufacturing, and test facilities are co-located in central Texas to enable rapid innovation and vertical integration across the company’s product lines. For more information, visit www.fireflyspace.com. Firefly utilizes its website as a means to distribute material information about the company to the public.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning Firefly. Statements included in this press release that are not statements of historical fact, including statements about our expectations, beliefs, plans, strategies, objectives, prospects, assumptions or future events or performance, are forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as “advance,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology. In particular, our outlook and revenue forecasts for full-year 2026, statements about our programs and innovation, our ability or expectations regarding our partnerships, collaborations and contract wins, our expectations regarding new vehicle launches and launch timelines, and our ability to retain existing customers and maintain their bookings are forward-looking statements.

Various risks that could cause actual results to differ from those expressed by the forward-looking statements included in this press release include, but are not limited to our failure to manage our growth effectively and our ability to achieve and maintain profitability; the potential for delayed or failed launches, and any failure of our launch vehicles and spacecraft to operate as intended; our inability to manufacture our launch vehicles, landers, or orbital vehicles at a quantity and quality that our customers demand; the hazards and operational risks that our products and service offerings are exposed to, including the wide and unique range of risks due to the unpredictability of space; the market for commercial launch services for small- and medium-sized payloads not achieving the growth potential we expect; adverse impacts from current or future disruptions in U.S. government operations, including as a result of delays or reduction in appropriations or regulatory approvals from our programs, or changes in U.S. government funding and budgetary priorities and spending levels; our dependence on contracts entered into in the ordinary course of business and our dependence on major customers and vendors; a loss of, or default by, one or more of our major customers, or a material adverse change in any such customer’s business or financial condition, could materially reduce our revenues and backlog; uncertain global macro-economic and political conditions, including the implementation of tariffs; the failure of our information technology systems, physical or electronic security protections; our failure to deliver engines, intellectual property, or certain services to AST SpaceMobile on the required timelines, or at all; the inability to operate Alpha at our anticipated launch rate (including due to potential regulatory delays) or finalize the development and delivery of Eclipse; our failure to establish and maintain important relationships with government agencies and prime contractors; the inability to realize our backlog; evolving government laws and regulations; our ability to consummate future acquisitions and successfully integrate operations in such acquisitions; our ability to implement and maintain effective internal control over financial reporting in the future; and the factors, risks and uncertainties included in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date stated, or if no date is stated, as of the date of this press release. Actual results may vary from the estimates provided. We undertake no intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events or otherwise, except as required by law.

Use of Non-GAAP Financial Measures

Adjusted EBITDA, Free Cash Flow, Non-GAAP Research and Development, Non-GAAP Selling, General, and Administrative, Non-GAAP Operating Expenses, Non-GAAP Loss from Operations, Non-GAAP Other Income (Expense), Non-GAAP Net Loss, and Non-GAAP Net Loss Per Share are non-GAAP financial measures. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP. A reconciliation of each non-GAAP financial measure to the most directly comparable financial measure prepared in accordance with U.S. GAAP is included in the supplemental financial data attached to this press release. Non-GAAP financial measures have important limitations as analytical tools and should not be considered in isolation or as a substitute for analyses of Firefly’s performance or cash flows as reported under U.S. GAAP. Non-GAAP financial measures may be defined differently by other companies in our industry and may not be comparable to similarly titled measures of other companies, thereby diminishing their utility.

Firefly believes non-GAAP financial information provides additional insight into the Company’s ongoing performance and liquidity. Therefore, Firefly provides this information to investors for a more consistent basis of comparison and to help them evaluate the Company’s ongoing performance and liquidity and to enable more meaningful period-to-period comparisons.


Adjusted EBITDA

We define Adjusted EBITDA as net loss, adjusted for provision for income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation expense, change in fair value of warrant liability, loss on extinguishment of debt, certain one-time costs related to the IPO, transaction-related expenses, gain on settlement of contingent liabilities, and certain other items that are not expected to recur in the future or that management does not view as reflective of the performance of the business. In addition to net loss, we use Adjusted EBITDA to evaluate our business, measure its performance, and make strategic decisions.

We believe that Adjusted EBITDA provides useful information to management, investors, and analysts in assessing our financial performance and results of operations across reporting periods by excluding items we do not believe are indicative of our core operating performance. Net loss is the U.S. GAAP measure most directly comparable to Adjusted EBITDA. Adjusted EBITDA should not be considered as an alternative to net loss. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.


Free Cash Flow

We define Free Cash Flow as net cash used in operating activities, less purchases of property and equipment and internal-use software. We believe that Free Cash Flow is a meaningful indicator of liquidity that provides information to management and investors about the amount of cash generated from or used in operations, after purchases of property and internal-use software, that (after any debt service requirements or other non-discretionary expenditures not otherwise deducted from the measure) can be used for strategic initiatives, including continuous investment in our business and strengthening our balance sheet.

Free Cash Flow has limitations as a liquidity measure, and you should not consider it in isolation or as a substitute for analysis of our cash flows as reported under U.S. GAAP. Free Cash Flow may be affected in the near to medium term by the timing of capital investments, fluctuations in our growth and the effect of such fluctuations on working capital, and our changes in our cash conversion cycle.


Non-GAAP Research and Development

We define Non-GAAP Research and Development as research and development, adjusted for stock-based compensation expense. Management believes this non-GAAP measure provides investors with meaningful insight into results from ongoing operations by excluding items of income or loss to present it in accordance with how management manages the business.


Non-GAAP Selling, General, and Administrative

We define Non-GAAP Selling, General and Administrative as selling, general and administrative, adjusted for amortization of acquired intangibles, stock-based compensation expense, certain one-time costs related to the IPO, transaction-related expenses, and certain other items that are not expected to recur in the future or that management does not view as reflective of the performance of the business. Management believes this non-GAAP measure provides investors with meaningful insight into results from ongoing operations by excluding items of income or loss to present it in accordance with how management manages the business.


Non-GAAP Operating Expenses

We define Non-GAAP Operating Expenses as operating expenses, adjusted for amortization of acquired intangibles, stock-based compensation expense, certain one-time costs related to the IPO, transaction-related expenses, and certain other items that are not expected to recur in the future or that management does not view as reflective of the performance of the business. Management believes this non-GAAP measure provides investors with meaningful insight into results from ongoing operations by excluding items of income or loss to present it in accordance with how management manages the business.


Non-GAAP Loss From Operations

We define Non-GAAP Loss From Operations as loss from operations, adjusted for amortization of acquired intangibles, stock-based compensation expense, certain one-time costs related to the IPO, transaction-related expenses, and certain other items that are not expected to recur in the future or that management does not view as reflective of the performance of the business. Management believes this non-GAAP measure provides investors with meaningful insight into results from ongoing operations by excluding items of income or loss to present it in accordance with how management manages the business.


Non-GAAP Other Income (Expense)

We define Non-GAAP Other Income (Expense) as other income (expense), adjusted for change in fair value of warrant liability, gain on settlement of contingent liabilities, loss on extinguishment of debt, and certain other items that are not expected to recur in the future or that management does not view as reflective of the performance of the business. Management believes this non-GAAP measure provides investors with meaningful insight into results from ongoing operations by excluding items of income or loss to present it in accordance with how management manages the business.


Non-GAAP Net Loss

We define Non-GAAP Net Loss as net loss, adjusted for the income tax effect of business acquisitions, amortization of acquired intangibles, stock-based compensation, change in fair value of warrant liability, loss on extinguishment of debt, certain one-time costs related to the IPO, transaction-related expenses, gain on settlement of contingent liabilities, and certain other items that are not expected to recur in the future or that management does not view as reflective of the performance of the business. Management believes this non-GAAP measure provides investors with meaningful insight into results from ongoing operations by excluding items of income or loss to present it in accordance with how management manages the business.

Contacts

Media Relations
[email protected] 

Investor Relations
[email protected] 

CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS AND COMPREHENSIVE LOSS

(unaudited; in thousands, except per share amounts)

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Revenue   $ 110,682     $ 30,778     $ 309,244     $ 102,182  
Cost of sales     85,385       22,288       242,611       87,477  
Gross profit     25,297       8,490       66,633       14,705  
Operating expenses                        
Research and development     75,991       48,763       215,032       142,549  
Selling, general, and administrative     50,884       21,920       144,044       47,243  
Total operating expenses     126,875       70,683       359,076       189,792  
Loss from operations     (101,578 )     (62,193 )     (292,443 )     (175,087 )
Other income (expense), net                        
Change in fair value of warrant liability     4,040       (42,150 )     (269 )     (47,257 )
Loss on extinguishment of debt     —       (30,400 )     —       (30,400 )
Interest income     4,460       5,289       14,770       8,078  
Interest expense     (1,637 )     (3,955 )     (7,036 )     (17,145 )
Gain on settlement of contingent liabilities     —       —       1,307       —  
Other income (expense), net     559       (3 )     552       4,528  
Total other income (expense), net     7,422       (71,219 )     9,324       (82,196 )
Loss before income taxes     (94,156 )     (133,412 )     (283,119 )     (257,283 )
Provision for income taxes     42       —       74       —  
Net loss and comprehensive loss     (94,198 )     (133,412 )     (283,193 )     (257,283 )
Less: Accretion of dividends of Series C Preferred Stock     —       (2,298 )     —       (13,240 )
Less: Accretion of dividends of Series D-1 Preferred Stock     —       (4,524 )     —       (21,989 )
Less: Accretion of dividends of Series D-3 Preferred Stock     —       (128 )     —       (394 )
Net loss available to common stockholders   $ (94,198 )   $ (140,362 )   $ (283,193 )   $ (292,906 )
                         
Net loss per common share                        
Basic and diluted   $ (0.56 )   $ (1.50 )   $ (1.73 )   $ (7.25 )
Weighted-average common shares outstanding                        
Basic and diluted     168,371       93,849       163,265       40,389  
                                 

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; in thousands, except per share amounts)

    September 30,     December 31,  
    2026     2025  
Assets            
Current assets            
Cash and cash equivalents   $ 409,285     $ 792,966  
Short-term investments     125,447       100,008  
Accounts receivable, net     56,412       46,129  
Advanced payments, current     79,664       12,350  
Contract assets     25,417       3,499  
Other current assets     19,159       8,223  
Total current assets     715,384       963,175  
Advanced payments, less current portion     14,380       60,496  
Property and equipment, net     197,397       163,738  
Right-of-use assets – operating leases     38,827       13,938  
Right-of-use assets – finance leases     2,527       3,735  
Intangible assets, net     147,706       165,709  
Goodwill     463,619       450,119  
Other assets, less current portion     2,119       4,024  
Total assets   $ 1,581,959     $ 1,824,934  
             
Liabilities, temporary equity, and stockholders’ equity            
Current liabilities            
Accounts payable   $ 66,820     $ 35,626  
Accrued expenses     43,423       42,755  
Accounts payable and accrued expenses – related parties     805       330  
Operating lease liability, current     4,039       1,161  
Finance lease liability, current     1,411       1,056  
Deferred revenue, current     171,172       116,135  
Notes payable, current     7,284       7,099  
Other current liabilities     17,533       9,419  
Total current liabilities     312,487       213,581  
Operating lease liability, less current portion     40,776       15,832  
Finance lease liability, less current portion     855       2,004  
Deferred revenue, less current portion     46,004       92,565  
Notes payable, less current portion     17,820       281,441  
Warrant liability     12,563       12,294  
Other liabilities, less current portion     7,928       17,278  
Total liabilities   $ 438,433     $ 634,995  
Stockholders’ equity            
Common stock, $0.0001 par value, 1,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 171,627 and 159,276 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     18       17  
Additional paid-in capital, net     2,446,980       2,210,201  
Accumulated deficit     (1,303,472 )     (1,020,279 )
Total stockholders’ equity     1,143,526       1,189,939  
Total liabilities and stockholders’ equity   $ 1,581,959     $ 1,824,934  
                 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited; in thousands)

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Cash flows from operating activities                        
Net loss   $ (94,198 )   $ (133,412 )   $ (283,193 )   $ (257,283 )
Adjustments to reconcile net loss to net cash used in operating activities:                        
Depreciation and amortization     13,293       5,623       43,181       13,539  
Stock-based compensation     15,292       4,000       44,831       5,191  
Change in fair value of warrant liability     (4,040 )     42,150       269       47,257  
Loss on extinguishment of debt     —       30,400       —       30,400  
Gain on settlement of contingent liabilities     —       —       (1,307 )     —  
Non-cash interest expense     428       1,009       1,249       4,595  
Non-cash interest income     (83 )     —       (2,444 )     —  
Changes in operating assets and liabilities:                        
Accounts receivable     1,703       511       (10,135 )     (4,123 )
Advanced payments     (12,183 )     (4,228 )     (20,556 )     34,550  
Contract assets     (5,478 )     —       (21,918 )     —  
Other assets     (1,829 )     3,242       (4,974 )     (996 )
Accounts payable     4,622       (1,956 )     25,471       (5,300 )
Accrued expenses     (7,761 )     (7,280 )     1,849       (5,035 )
Accounts payable and accrued expenses – related parties     (641 )     349       475       704  
Other liabilities     12,162       (622 )     818       (11,812 )
Right-of-use assets     2,487       563       4,333       1,549  
Lease liabilities     (1,111 )     (4,583 )     (235 )     (6,646 )
Deferred revenue     7,637       11,188       8,476       15,745  
  Net cash used in operating activities     (69,700 )     (53,046 )     (213,810 )     (137,665 )
Cash flows from investing activities                        
Purchases of property and equipment and internal-use software     (15,559 )     (8,920 )     (56,648 )     (20,757 )
Purchases of short-term investments     —       —       (125,000 )     —  
Payments for acquisitions of businesses, net of acquired cash     —       —       (3,699 )     —  
Proceeds from sale of short-term investments     50,000       —       100,008       —  
  Net cash used in investing activities     34,441       (8,920 )     (85,339 )     (20,757 )
Cash flows from financing activities                        
Proceeds from issuance of common stock     —       943,736       184,111       943,736  
Payments of offering costs     (1,055 )     (4,208 )     (2,557 )     (4,208 )
Proceeds from issuance of Preferred Stock     —       51,390       —       235,506  
Principal payments on finance leases     (264 )     (283 )     (796 )     (1,166 )
Payments of notes payable     (1,918 )     (128,262 )     (5,863 )     (131,457 )
Payment of IPO Closing Preferred Stock Dividend     —       (4,990 )     —       (4,990 )
Repayment of notes payable – related parties     —       (21,117 )     —       (21,117 )
Payments of debt issuance costs     (171 )     (1,508 )     (1,359 )     (2,083 )
Proceeds from repayment of employee note     18       13       43       396  
Proceeds from issuance of notes payable     —       —       1,730       —  
Repayment of Revolving Credit Facility     —       —       (260,000 )     —  
Proceeds from exercise of stock options, net of shares withheld for taxes     (11,883 )     1,643       159       2,238  
  Net cash (used in) provided by financing activities     (15,273 )     836,414       (84,532 )     1,016,855  
Net (decrease) increase in cash and cash equivalents and restricted cash     (50,532 )     774,448       (383,681 )     858,433  
Cash and cash equivalents and restricted cash                        
Balance, beginning of period     459,817       221,543       792,966       137,558  
Balance, end of period   $ 409,285     $ 995,991     $ 409,285     $ 995,991  
Reconciliation of cash and cash equivalents and restricted cash                        
Cash and cash equivalents   $ 409,285     $ 995,162     $ 409,285     $ 995,162  
Restricted cash     —       829       —       829  
Total cash and cash equivalents and restricted cash at the end of the period   $ 409,285     $ 995,991     $ 409,285     $ 995,991  
                                 

    For the Three Months
Ended September 30,
  For the Nine Months
Ended September 30,
    2026   2025   2026   2025
Supplemental disclosures of cash flow information                
Cash paid for interest   $ 1,423   $ 3,342   $ 6,969   $ 14,443
Non-cash investing and financing activities                
Increase in accounts payable for property and equipment   $ 1,465   $ 492   $ 2,577   $ 1,905
Property and equipment acquired through loans   $ —   $ —   $ 642   $ —
Capitalized interest (paid-in-kind)   $ —   $ 573   $ —   $ 683
Equity issued for business combinations   $ —   $ —   $ 10,144   $ —
Issuance of debt in exchange for software licenses and obligations   $ —   $ —   $ —   $ 664
Acquisition of internal-use software licenses and obligations   $ 756   $ 10,633   $ 4,297   $ 10,633
Right-of-use asset acquired in exchange for operating lease liabilities   $ 4,857   $ —   $ 9,923   $ —
Right-of-use asset acquired in exchange for finance lease liabilities   $ —   $ —   $ —   $ 1,625
Net exercise of Common Warrants into common stock   $ —   $ 46,060   $ —   $ 46,060
Unpaid deferred offering costs associated with IPO   $ —   $ 7,195   $ —   $ 7,195
Preferred Stock issuance costs not yet paid   $ —   $ 3,510   $ —   $ 3,510
Issuance of common stock to settle Preferred Stock Dividend   $ —   $ 86,124   $ —   $ 86,124
Conversion of Preferred Stock to common stock upon IPO   $ —   $ 937,087   $ —   $ 937,087
Non-cash purchase consideration for acquisitions of businesses   $ —   $ —   $ 5,438   $ —
                         

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(unaudited; in thousands)

The following tables present reconciliations of Adjusted EBITDA, Free Cash Flow, Non-GAAP Research and Development, Non-GAAP Selling, General, and Administrative, Non-GAAP Operating Expenses, Non-GAAP Other Income (Expense), Non-GAAP Net Loss, and Non-GAAP Net Loss Per Share to their most directly comparable financial measures presented in accordance with U.S. GAAP:

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Net loss   $ (94,198 )   $ (133,412 )   $ (283,193 )   $ (257,283 )
Adjusted for:                        
Provision for income taxes     42       —       74       —  
Interest income     (4,460 )     (5,289 )     (14,770 )     (8,078 )
Interest expense     1,637       3,955       7,036       17,145  
Depreciation and amortization     13,627       6,447       44,389       14,363  
Stock-based compensation expense     15,292       4,000       44,831       5,191  
Change in fair value of warrant liability     (4,040 )     42,150       269       47,257  
Loss on extinguishment of debt     —       30,400       —       30,400  
One-time costs related to the IPO(1)     —       3,792       —       8,012  
Transaction-related expenses     2,587       1,528       7,220       1,528  
Gain on settlement of contingent liabilities     —       —       (1,307 )     —  
Other(2)     (14 )     97       1       97  
Adjusted EBITDA   $ (69,527 )   $ (46,332 )   $ (195,450 )   $ (141,368 )
                         
    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Net cash used in operating activities   $ (69,700 )   $ (53,046 )   $ (213,810 )   $ (137,665 )
Purchases of property and equipment and internal-use software     (15,559 )     (8,920 )     (56,648 )     (20,757 )
Free Cash Flow   $ (85,259 )   $ (61,966 )   $ (270,458 )   $ (158,422 )

(1) Represents costs incurred related to the IPO that do not meet the direct and incremental criteria per SEC Staff Accounting Bulletin Topic 5.A that were netted against the gross proceeds of the IPO and are not expected to recur in the future.

(2) Other includes (gain) loss on foreign exchange and executive severance.

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Research and development   $ 75,991     $ 48,763     $ 215,032     $ 142,549  
Stock-based compensation expense     (8,279 )     (501 )     (22,682 )     (796 )
Non-GAAP Research and Development   $ 67,712     $ 48,262     $ 192,350     $ 141,753  
                         
Selling, general, and administrative   $ 50,884     $ 21,920     $ 144,044     $ 47,243  
Amortization of acquired intangibles     (5,000 )     —       (15,000 )     —  
Stock-based compensation expense     (7,013 )     (3,499 )     (22,149 )     (4,395 )
One-time costs related to the IPO(1)     —       (3,792 )     —       (8,012 )
Transaction-related expenses     (2,587 )     (1,528 )     (7,220 )     (1,528 )
Other(2)     —       (97 )     —       (97 )
Non-GAAP Selling, General, and Administrative   $ 36,284     $ 13,004     $ 99,675     $ 33,211  
                         
Operating expenses   $ 126,875     $ 70,683     $ 359,076     $ 189,792  
Amortization of acquired intangibles     (5,000 )     —       (15,000 )     —  
Stock-based compensation expense     (15,292 )     (4,000 )     (44,831 )     (5,191 )
One-time costs related to the IPO(1)     —       (3,792 )     —       (8,012 )
Transaction-related expenses     (2,587 )     (1,528 )     (7,220 )     (1,528 )
Other(2)     —       (97 )     —       (97 )
Non-GAAP Operating Expenses   $ 103,996     $ 61,266     $ 292,025     $ 174,964  
                         
Loss from operations   $ (101,578 )   $ (62,193 )   $ (292,443 )   $ (175,087 )
Amortization of acquired intangibles     5,000       —       15,000       —  
Stock-based compensation expense     15,292       4,000       44,831       5,191  
One-time costs related to the IPO(1)     —       3,792       —       8,012  
Transaction-related expenses     2,587       1,528       7,220       1,528  
Other(2)     —       97       —       97  
Non-GAAP Loss from Operations   $ (78,699 )   $ (52,776 )   $ (225,392 )   $ (160,259 )
                         
Other income (expense)   $ 7,422     $ (71,219 )   $ 9,324     $ (82,196 )
Change in fair value of warrant liabilities     (4,040 )     42,150       269       47,257  
Gain on settlement of contingent liabilities     —       —       (1,307 )     —  
Loss on extinguishment of debt     —       30,400       —       30,400  
Other(2)     (14 )     —       1       —  
Non-GAAP Other Income (Expense)   $ 3,368     $ 1,331     $ 8,287     $ (4,539 )
                         
Net loss   $ (94,198 )   $ (133,412 )   $ (283,193 )   $ (257,283 )
Income tax effect of business acquisitions     —       —       128       —  
Amortization of acquired intangibles     5,000       —       15,000       —  
Stock-based compensation     15,292       4,000       44,831       5,191  
Change in fair value of warrant liability     (4,040 )     42,150       269       47,257  
Loss on extinguishment of debt     —       30,400       —       30,400  
One-time costs related to the IPO(1)     —       3,792       —       8,012  
Transaction-related expenses     2,587       1,528       7,220       1,528  
Gain on settlement of contingent liabilities     —       —       (1,307 )     —  
Other(2)     (14 )     97       1       97  
Non-GAAP Net Loss   $ (75,373 )   $ (51,445 )   $ (217,051 )   $ (164,798 )
                         
Basic and diluted weighted average shares outstanding     168,371       93,849       163,265       40,389  
                         
GAAP net loss per share, basic and diluted   $ (0.56 )   $ (1.50 )   $ (1.73 )   $ (7.25 )
Non-GAAP net loss per share, basic and diluted   $ (0.45 )   $ (0.55 )   $ (1.33 )   $ (4.08 )

(1) Represents costs incurred related to the IPO that do not meet the direct and incremental criteria per SEC Staff Accounting Bulletin Topic 5.A that were netted against the gross proceeds of the IPO and are not expected to recur in the future.

(2) Other includes (gain) loss on foreign exchange and executive severance.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/09da17c2-1408-4bda-8bd3-548379915069



Marchex Returns to Revenue Growth and Profitability in Third Quarter 2026


Generates $1.3 Million in GAAP Net Income and $2.6 Million in Adjusted EBITDA (net of reorganization costs)


Highlights Early Commercial Momentum Following Archenia Acquisition; Appoints Travis Fairchild President

SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) — Marchex, Inc. (NASDAQ: MCHX), a vertically focused, AI-driven conversation analytics, customer acquisition, and optimization company, today announced financial results for the third quarter ended September 30, 2026.


Third Quarter 2026 Financial Highlights (Prior Year Results As Adjusted)

  • Revenue increased to $16.0 million, up from $15.2 million in the third quarter of 2025. 
  • Net income was $1.3 million, or $0.03 per diluted share, compared with a net loss of $1.3 million, or $(0.03) per diluted share, in the third quarter of 2025.
  • Adjusted EBITDA increased to $2.4 million, compared with $0.5 million in the prior year period, with Adjusted EBITDA margin expanding to approximately 15% from 3% in the third quarter of 2025. Adjusted EBITDA includes $0.2 million of reorganization and acquisition-related costs. Adjusted EBITDA before those costs was $2.6 million, or 16%.
  • Adjusted non-GAAP income per share was $0.04, compared with an Adjusted non-GAAP loss of ($0.01) per share in the prior year period.

“Our third quarter results reflect a new phase of growth and meaningful progress in strengthening Marchex’s financial performance, with year-over-year revenue growth, positive GAAP net income, and a significant improvement in Adjusted EBITDA,” said Russell Horowitz, Chairman of Marchex. “At the same time, we are seeing encouraging early commercial traction following our combination with Archenia, including expanded customer relationships, new AI-powered solutions deployments, and increased opportunities to cross-sell our combined capabilities.

“By bringing together Marchex’s conversational intelligence and analytics with Archenia’s AI-powered customer qualification and acquisition technologies, we are creating a differentiated platform that connects customer insights with automated actions and measurable business outcomes. We believe this positions us to capture a greater share of customer spending, expand our market opportunity, and drive profitable growth over time. As we build on our early commercial momentum, we are focused on scaling the business while maintaining financial discipline.”


Customer, Product, and Growth Initiatives

Marchex continues to make progress commercializing its combined AI-powered conversational intelligence, customer qualification, and acquisition technologies. Recent customer developments demonstrate the potential to expand existing relationships, generate incremental revenue, and broaden distribution of the Company’s solutions.

Key developments include:

• Expanded AI Voice Agent Deployment: Marchex expanded its relationship with an existing advertising and media customer by deploying its AI Voice Agent solution commercially after a successful paid pilot. The customer relationship, which currently generates approximately $400,000 in annualized revenue, is expected to generate additional revenue in 2026 and more than $200,000 in incremental annualized revenue in 2027. The deployment demonstrates Marchex’s ability to cross-sell AI-powered solutions to existing customers and to expand revenue opportunities by helping customers capture qualified leads and sales opportunities that might otherwise be missed.

• Expanded Automotive OEM Distribution: Marchex received approval from a major automotive original equipment manufacturer (OEM) to offer its Engage for Service solution through the OEM’s dealer portal, expanding distribution opportunities and enabling dealers to access OEM co-op funding for the solution. Engage for Service was previously deployed in a pilot with 75 dealerships, where it improved service operations and identified missed appointment and revenue opportunities. The approval provides a potentially scalable distribution channel to expand adoption of Engage for Service across the OEM’s dealership network.

The Company believes these developments highlight its ability to accelerate adoption of its AI-powered solutions with meaningful cross-selling and bundling opportunities across its established enterprise customer relationships, as well as create opportunities to win new customers and unlock new markets.

Following the July 2026 acquisition of Archenia, Marchex has been focused on integrating the companies’ complementary technologies and developing solutions that combine conversational intelligence with AI-powered customer qualification, automated engagement, and verified business outcomes. These capabilities enable customers to move beyond analyzing consumer interactions to taking the automated actions designed to improve customer acquisition, appointment conversion, and revenue generation.


Marchex Appoints Travis Fairchild President

Marchex also announced that Travis Fairchild has been appointed President of the combined company, effective November 9, 2026. Fairchild previously served as Chief Executive Officer of Archenia, which Marchex acquired in July 2026, and brings extensive experience in AI-powered customer engagement, strategic development, and enterprise technology solutions.

Fairchild’s appointment reflects the Company’s focus on accelerating commercialization of its combined platform and increasing adoption of Marchex’s AI-powered customer acquisition and engagement solutions. Prior to Archenia, he was with Marchex in several senior roles.

“Travis brings a unique combination of deep institutional knowledge of Marchex, entrepreneurial leadership, and hands-on experience building and scaling AI-powered customer engagement solutions,” said Horowitz. “Having successfully led Archenia and played a key role in bringing our two businesses together, he is exceptionally well positioned to accelerate the commercialization of our combined capabilities, deepen customer relationships, and drive the next phase of growth.”

Fairchild served as CEO of Archenia beginning in 2021, where he led the company’s strategy, sales, product development, and AI initiatives. Previously, he spent 18 years at Marchex in strategy and business development roles, helping expand the Company’s call analytics capabilities, execute strategic acquisitions, and develop solutions for Fortune 500 customers.

Troy Hartless, previously President of Marchex, will continue to serve as Chief Revenue Officer focused on new and emerging opportunities and sales channels.


Financial Outlook

THE FOLLOWING FORWARD-LOOKING STATEMENTS REFLECT MARCHEX’S EXPECTATIONS AS OF NOVEMBER 10, 2026

The Company currently anticipates that the financial results for the three months ending December 31, 2026 will be in the range of (in millions):

  Fourth Quarter 2026 (outlook)
Revenue $15.0 or more
Adjusted EBITDA, net of reorganization and acquisition costs $2.3 – $2.5

Marchex notes that seasonality in the fourth quarter based on lower conversational volumes typically leads to lower sequential revenue and Adjusted EBITDA. The fourth quarter forecast largely assumes such seasonality, although Marchex believes that based on its current sales pipeline and cost efficiencies, there may be opportunities to offset and potentially outperform such typical seasonality depending on the timing and formalization of opportunities, which would also provide additional visibility on growth acceleration into 2027. Marchex will provide its initial 2027 financial outlook when it reports its Fourth Quarter 2026 Financial results, currently anticipated in early March 2027.

Marchex expects to continue building on the operational progress achieved during the third quarter while pursuing new revenue opportunities arising from the combination with Archenia. The Company remains focused on expanding adoption of its AI-powered solutions, deepening relationships with existing customers, and maintaining disciplined expense management.

Looking ahead to 2027, Marchex believes that combining its conversational intelligence capabilities with Archenia’s customer acquisition and qualification technologies will create meaningful opportunities to accelerate revenue growth and expand operating leverage. The Company intends to selectively invest in sales and product development to capitalize on these opportunities while maintaining a disciplined approach to expense management and long-term profitability.


About Marchex

Marchex harnesses proprietary AI-powered conversational intelligence and advanced customer acquisition technologies to help businesses transform consumer intent into actionable, outcome-driven business results. Through its combination with Archenia, the Company integrates prescriptive analytics, omnichannel intelligence, AI-powered qualification, and automated engagement capabilities into a comprehensive customer acquisition and optimization platform. 

Leveraging real-time AI signals, machine-learning models, and deep vertical market expertise, Marchex helps organizations identify consumer intent, improve customer engagement, increase conversion rates, and generate revenue growth. The Company serves leading businesses across major verticals, including automotive, insurance, home services, healthcare, and advertising/media.

Please visit www.marchex.com or follow Marchex on LinkedIn, where the Company discloses material information from time to time about its business and financial performance.


Forward-Looking Statements

Certain statements included above contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included herein regarding the Company’s strategy, future operations, future financial position, future revenues, other financial guidance, acquisitions, dispositions, projected costs, prospects, plans and objectives of management are forward-looking statements. The Company may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on such statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in such statements due to a number of important factors, including but not limited to product demand, order cancellations and delays, competition, changes in business strategy or development plans, and general economic and business conditions. These factors are described in greater detail in the “Risk Factors” section of the Company’s most recent periodic report or registration statement filed with the SEC. All of the information provided herein is as of November 10, 2026 and the Company undertakes no duty to update the information provided herein.

In the event the earnings release contains links to third party websites or materials, the links are provided solely as a convenience to the user. Marchex is not responsible for the content of linked third-party sites or materials and does not make any representations regarding the content or accuracy thereof.


Non-GAAP Financial Information

To supplement Marchex’s consolidated financial statements presented in accordance with GAAP and to provide clarity internally and externally, Marchex uses certain non-GAAP measures of financial performance and liquidity, including adjusted EBITDA and adjusted non-GAAP income (loss) per share. Financial analysts and investors may use adjusted EBITDA to help with comparative financial evaluation to make informed investment decisions. Financial analysts and investors may use adjusted non-GAAP income (loss) per share to analyze Marchex’s financial performance since these groups have historically used earnings per share related measures, along with other measures, to estimate the value of a Company, to make informed investment decisions, and to evaluate a Company’s operating performance compared to that of other companies in its industry.


Adjusted EBITDA
represents net income (loss) before (1) interest, (2) income taxes, (3) amortization of intangible assets from acquisitions, (4) depreciation and amortization, (5) stock-based compensation expense, and (6) acquisition and disposition-related costs. Adjusted EBITDA is a metric by which Marchex has evaluated the performance of its business, to include being the basis on which Marchex’s internal budgets have been based and by which Marchex’s management has been evaluated. This measure is used by our management to understand and evaluate our core operating performance and trends, and management believes it provides meaningful information regarding the Company’s liquidity and ability to fund its operations and financing obligations.


Adjusted non-GAAP income (loss) per share
represents adjusted non-GAAP income (loss) divided by GAAP diluted shares outstanding. Adjusted non-GAAP income (loss) generally captures those items on the statement of operations that have been, or ultimately will be, settled in cash exclusive of certain items that are not indicative of Marchex’s recurring core operating results and represents net income (loss) applicable to common stockholders plus the net of tax effects of: (1) stock-based compensation expense, (2) acquisition and disposition related costs, (3) amortization of intangible assets from acquisitions, and (4) interest (income) expense and other, net.

Marchex’s management believes that investors should have access to, and Marchex is obligated to provide, the same set of tools that management uses in analyzing the Company’s results. These non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, and should not be considered in isolation, as a substitute for, or superior to, GAAP results. Marchex’s non-GAAP financial measures may be defined differently from time to time and may be defined differently than similar titled terms used by other companies, and accordingly, care should be exercised in understanding how Marchex defines its non-GAAP financial measures in this release. Marchex endeavors to compensate for the limitations of the non-GAAP measures presented by providing the comparable GAAP measure with equal or greater prominence, GAAP financial statements, and detailed descriptions of the reconciling items and adjustments, including quantifying such items, to derive the non-GAAP measure.

For further information, contact:

Marchex Investor Relations
Email: [email protected]

Or

Marchex Corporate Communications
Email: [email protected]

MARCHEX, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(In Thousands, except per share amounts)

(Unaudited)

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025 (As Adjusted)     2026     2025 (As Adjusted)  
Revenue   $ 15,974     $ 15,192     $ 45,874     $ 49,039  
Expenses:                        
Cost of revenue(1)     7,708       7,011       22,036       22,750  
Amortization of capitalized software development costs     129       29       322       39  
Total cost of revenue(1)     7,837       7,040       22,358       22,789  
Sales and marketing(1)     2,624       3,319       9,281       10,867  
Product development(1)     2,016       2,736       6,965       8,904  
General and administrative(1)     2,059       3,243       7,384       9,496  
Total operating expenses   $ 14,536     $ 16,338     $ 45,988     $ 52,056  
Income (loss) from operations     1,438       (1,146)       (114)       (3,017)  
Interest income (expense) and other, net     (164)       (120)       (432)       367  
Income (loss) before income tax expense     1,274       (1,266)       (546)       (2,650)  
Income tax expense     —       27       310       148  
Net income (loss) applicable to common stockholders   $ 1,274     $ (1,293)     $ (856)     $ (2,798)  
Basic and diluted net income (loss) per Class A and B share applicable to common stockholders   $ 0.03     $ (0.03)     $ (0.02)     $ (0.06)  
Shares used to calculate basic net income (loss) per share applicable to common stockholders:                        
Class A     4,661       4,661       4,661       4,661  
Class B     39,679       39,247       39,546       39,183  
Shares used to calculate diluted net income (loss) per share applicable to common stockholders:                        
Class A     4,661       4,661       4,661       4,661  
Class B     44,340       43,908       44,207       43,844  
(1)Includes stock-based compensation allocated as follows:                        
Cost of revenue   $ 12     $ 4     $ 22     $ 8  
Sales and marketing     208       100       575       297  
Product development     117       70       318       175  
General and administrative     228       793       765       1,594  
Total   $ 565     $ 967     $ 1,680     $ 2,074  

MARCHEX, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(In Thousands)

    (Unaudited)        
    September 30,     December 31,  
    2026     2025 (As Adjusted)  
Assets            
Current assets:            
Cash and cash equivalents   $ 8,671     $ 10,301  
Accounts receivable, net     9,517       8,654  
Prepaid expenses     1,823       1,042  
Other current assets     993       1,475  
Total current assets     21,004       21,472  
Property and equipment, net     2,392       1,932  
Other assets, net     377       564  
Right-of-use lease assets     —       668  
Goodwill     17,558       17,558  
Total assets   $ 41,331     $ 42,194  
Liabilities and Stockholders’ Equity            
Current liabilities:            
Accounts payable   $ 5,372     $ 4,674  
Accrued benefits and payroll     909       1,412  
Other accrued expenses and current liabilities     2,610       3,060  
Deferred revenue and deposits     384       598  
Related party obligations and related amounts, current     4,910       —  
Contingent earn-out, current     2,464       —  
Operating lease liability, current     396       355  
Total current liabilities     17,045       10,099  
Deferred tax liabilities     871       664  
Operating lease liability, non-current     —       366  
Related party obligations, related amounts, and other non-current liabilities     6,686       2,766  
Contingent earn-out, non-current     1,991       —  
Total liabilities   $ 26,593     $ 13,895  
Stockholders’ equity:            
Class A common stock   $ 49     $ 49  
Class B common stock     397       392  
Additional paid-in capital     352,086       364,796  
Accumulated deficit     (337,794)       (336,938)  
Total stockholders’ equity     14,738       28,299  
Total liabilities and stockholders’ equity   $ 41,331     $ 42,194  

MARCHEX, INC. AND SUBSIDIARIES

(In Thousands)

(Unaudited)

Reconciliation of Net Income (Loss) to Adjusted EBITDA

                   
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025 (As Adjusted)     2026     2025 (As Adjusted)  
Net income (loss) applicable to common stockholders   $ 1,274     $ (1,293)     $ (856)     $ (2,798)  
Interest expense (income) and other, net     164       120       432       (367)  
Income tax expense     —       27       310       148  
Amortization of capitalized software development costs     138       31       348       42  
Depreciation and amortization     233       626       1,326       1,911  
Stock-based compensation     565       967       1,680       2,074  
Adjusted EBITDA   $ 2,374     $ 478     $ 3,240     $ 1,010  

MARCHEX, INC. AND SUBSIDIARIES

(In Thousands)

(Unaudited)

Reconciliation of Net Income (Loss) per Share to Adjusted Non-GAAP Income (Loss) per Share

(1)

   

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025 (As Adjusted)     2026     2025 (As Adjusted)  
Net income (loss) per share applicable to common stockholders, diluted   $ 0.03     $ (0.03)     $ (0.02)     $ (0.06)  
Stock-based compensation     0.01       0.02       0.04       0.05  
Interest income (expense) and other, net     —       —       (0.01)       0.01  
Adjusted non-GAAP income (loss) per share   $ 0.04     $ (0.01)     $ 0.01     $ 0.00  
Shares used to calculate diluted net income (loss) per share applicable to common stockholders (GAAP) and adjusted non-GAAP income (loss) per share     44,340       43,908       44,207       43,844  

(1) For the purpose of computing the number of diluted shares for adjusted non-GAAP income (loss) per share, Marchex uses the accounting guidance that would be applicable for computing the number of diluted shares for GAAP net income (loss) per share.



Shoe Station Group to Report Third Quarter 2026 Results on November 24, 2026

Shoe Station Group to Report Third Quarter 2026 Results on November 24, 2026

FORT MILL, S.C.–(BUSINESS WIRE)–Shoe Station Group, Inc. (Nasdaq: SHOE) (the “Company”), a leading omnichannel retailer of footwear and accessories for the family, today announced that third quarter 2026 earnings results will be released on Tuesday, November 24, 2026, before the market open. The Company will host its quarterly conference call to discuss third quarter 2026 results at 9:00 a.m. Eastern Time.

The earnings call will be webcast and can be accessed in the Investors section of the Company’s website at investors.shoestationgroupinc.com. An online replay of the conference call will be available shortly after the call and will be available for one year.

About Shoe Station Group

Shoe Station Group, Inc. is one of the nation’s largest omnichannel family footwear retailers, offering a broad assortment of dress, casual and athletic footwear for men, women and children with emphasis on national name brands. As of November 10, 2026, the Company operated 420 stores in 35 states and Puerto Rico under its Shoe Carnival and Shoe Station banners and offers shopping at www.shoecarnival.com and www.shoestation.com. Headquartered in Fort Mill, SC, and with distribution and support operations located in Evansville, IN, Shoe Station Group, Inc. trades on The Nasdaq Stock Market LLC under the symbol SHOE.

W. Kerry Jackson
Chief Financial Officer
(812) 867-4034
[email protected]

KEYWORDS: United States North America North Carolina South Carolina

INDUSTRY KEYWORDS: Children Online Retail Discount/Variety Women Fashion Men Catalog Retail Family Consumer Teens

MEDIA:

Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

  • BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized.
  • BACKBEAT Trial primary endpoint data planned to be submitted for late-breaking presentation at the Heart Rhythm Society 2027 (“HRS 2027”).
  • Medtronic planning to submit AVIM Therapy
    Premarket Approval (“PMA”) supplement to the FDA following data presentation, assuming positive trial results.
  • Site activation and patient enrollment accelerating in the Virtue Trial, the Company’s U.S. Investigational Device Exemption (“IDE”) pivotal trial comparing Virtue SAB head-to-head with the commercially available AGENT™ paclitaxel-coated balloon for coronary In-Stent Restenosis.
  • Raised approximately $80.5 million in net proceeds through an underwritten public offering of common stock, which closed on November 9, 2026, including proceeds from the underwriters’ full exercise of their option to purchase additional shares. 
  • $101.9 million of cash and cash equivalents, and marketable securities as of September 30, 2026 and public offering proceeds provide projected cash runway through 2028.
  • Company hosting R&D Day on Thursday, November 12, 2026, in New York City and via live webcast, featuring in-depth reviews of AVIM Therapy and Virtue SAB with leading physician investigators.

NEW HOPE, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced financial results for the third quarter ended September 30, 2026, and provided a business update on its two pivotal-stage investigational cardiovascular programs: Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) for the treatment of uncontrolled hypertension, for which the Company has a strategic collaboration with Medtronic (NYSE: MDT) for the treatment of pacemaker-indicated patients, and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) for the treatment of coronary artery disease.

David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, stated, “With the completion of enrollment of the BACKBEAT Trial, AVIM Therapy is nearing pivotal primary endpoint results. Alongside our collaborators at Medtronic, we now move to the completion of three-month follow-up in all patients, locking the primary endpoint database, and submitting a robustly powered data set for late-breaking presentation at HRS 2027 in May. We believe the results from the BACKBEAT Trial could set AVIM Therapy on a clear course to redefining the clinical impact of cardiac pacing and provide a powerful new therapeutic option for millions of higher-risk hypertensive patients who remain above blood pressure target despite medication.”

Hochman continued, “The third quarter also saw Virtue Sirolimus AngioInfusion™ Balloon advance in its own IDE pivotal, randomized trial. The Virtue® Trial is testing Virtue SAB’s fundamentally different approach to arterial drug delivery, liquid infusion of SirolimusEFR™ directly into the vessel wall without the need for a fragile balloon coating. We are also grateful to our new and existing shareholders that participated in the oversubscribed public equity offering we closed yesterday. The net proceeds from our public offering along with the over $100 million we had at the end of the quarter provide funding through 2028. We are in a strong position to deliver key value-creating milestones for both pivotal stage programs and support Medtronic as they drive toward potential global commercialization of AVIM Therapy. We look forward to showcasing both of our high-impact therapeutic device platforms at our investor R&D Day this Thursday, where leading physician investigators will join us to examine the clinical and commercial potential of AVIM Therapy and Virtue SAB.”

Q3 2026 and Recent Business Highlights:

  • Completed enrollment in the BACKBEAT Trial in collaboration with Medtronic. A total of 349 patients with uncontrolled hypertension and an implanted dual-chamber pacemaker were randomized across 92 sites in 15 countries. Orchestra BioMed and Medtronic intend to submit primary endpoint results for late-breaking presentation consideration at HRS 2027.
  • Received written confirmation from FDA that Medtronic’s marketing submission for AVIM Therapy will be a PMA supplement. The submission is planned to be made promptly following presentation of the primary endpoint results of the BACKBEAT Trial, assuming positive trial results.
  • Advanced site activation and patient enrollment in the Virtue Trial, the Company’s U.S. IDE pivotal trial comparing Virtue SAB head-to-head with the commercially available AGENT™ paclitaxel-coated balloon for coronary in-stent restenosis (“ISR”). The prospective, multicenter, randomized, single-blind, non-inferiority trial has a planned enrollment of approximately 740 patients, with an enrollment completion target date by the end of 2027.
  • Virtue SAB mechanistic and clinical evidence presented at Transcatheter Cardiovascular Therapeutics 2026. On November 1, 2026, Allen Jeremias, MD, Co-Principal Investigator of the Virtue Trial, presented Virtue SAB’s differentiated mechanism of action for infusing a large liquid volume of submicron, particle-encapsulated SirolimusEFR™ directly into the vessel wall. Dr. Jeremias also outlined existing preclinical and clinical evidence and the pivotal IDE trial design.
  • AVIM Therapy was featured in two sessions at HRX Live 2026 in Atlanta, including a sponsored roundtable on the Medtronic–Orchestra BioMed strategic collaboration and a panel exploring the expanding role of permanent cardiac pacing beyond bradycardia. The discussions highlighted AVIM Therapy’s mechanism of action, clinical evidence and potential in hypertensive heart disease. A recording of the roundtable is available on the Company’s website.
  • Received a $6.1 million milestone payment on September 14, 2026, in connection with Haemonetics Corporation’s (NYSE: HAE) acquisition of Vivasure Medical Limited (“Vivasure”). Together with approximately $5 million received in January 2026, total cash proceeds received from the transaction are approximately $11 million. The FDA recently approved the PerQseal® Elite vascular closure system, originally developed by Vivasure, for large-bore arterial procedures.

Public Offering

On November 9, 2026, the Company closed an underwritten public offering of 17,250,000 shares of its common stock at a price to the public of $5.00 per share, resulting in net proceeds to the Company of approximately $80.5 million (including proceeds from the underwriters’ full exercise of their option to purchase additional shares), after deducting underwriting discounts and commissions and estimated offering expenses (the “Public Offering”).

R&D Day: Thursday, November 12, 2026

The Company will host its R&D Day on Thursday, November 12, 2026, at 3:00 p.m. ET in New York City and via live webcast. Company leadership, leading cardiologists and trial investigators will discuss the clinical and treatment burden associated with uncontrolled hypertension in pacemaker-indicated patients and restenosis in coronary stent interventions, the potential for AVIM Therapy and Virtue SAB to address these unmet needs, key upcoming clinical milestones and the commercial potential of AVIM Therapy and Virtue SAB. Physician speakers include Vivek Reddy, MD, Marat Fudim, MD, Dean Kereiakes, MD, and Allen Jeremias, MD. Webcast of the R&D Day is available for registered participants and a replay of the event will be available through the Investors section of the Company’s website.

Financial Results for the Third Quarter Ended September 30, 2026

  • Cash and cash equivalents and Marketable securities totaled $101.9 million as of September 30, 2026, not including the $80.5 million in net proceeds from the Public Offering.
  • Net cash used in operating activities and for the purchase of fixed assets was $19.9 million during the third quarter of 2026, compared with $14.9 million for the third quarter in 2025, with the primary drivers being increased research and development costs, including clinical trial activities, as well as personnel and consulting expenditures during the third quarter of 2026.
  • Research and development expenses for the third quarter of 2026 were $17.7 million, compared with $14.0 million for the third quarter in 2025, which represents an increase of 26%. The increase was primarily due to additional costs associated with the ongoing BACKBEAT Trial and to advance the Virtue SAB program, including the Virtue Trial.
  • Selling, general and administrative expenses for the third quarter of 2026 were $5.6 million, compared with $7.1 million for the third quarter of 2025, which represents a decrease of 21%. The decrease was primarily due to a decrease in legal and professional fees.
  • Net loss attributable to common stockholders for the third quarter of 2026 was $19.6 million, or ($0.30) per share, compared with a net loss attributable to common stockholders of $20.8 million, or ($0.40) per share, for the third quarter of 2025, which represents a decrease of 6%. Net loss attributable to common stockholders for the third quarter of 2026 included $3.4 million in net interest expense for the third quarter of 2026 as compared to $1.2 million for the same period in 2025, of which a portion was non-cash in each period. Non-cash stock-based compensation expense was $2.3 million as compared to $3.0 million for the same period in 2025.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities.

AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial, and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations. The BACKBEAT Trial has completed enrollment.

Virtue SAB is a first-of-its-kind, non-coated drug delivery AngioInfusion balloon system designed to infuse a large liquid dose of a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB exceeded the published tissue concentrations of leading limus drug-eluting stents and demonstrated positive three-year clinical data in coronary ISR in the SABRE study, a multicenter, prospective, independent core laboratory–adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease, and below-the-knee peripheral artery disease, in each case, within specified parameters. The Virtue Trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis is currently enrolling patients.

CAUTION: Investigational devices. Limited by United States law to investigational use.

For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the enrollment, timing, implementation, results and design of the Company’s ongoing pivotal trials, the timing of the presentation of clinical data, the timing of regulatory submissions, realizing the clinical and commercial value of AVIM Therapy and Virtue SAB, the potential safety and efficacy of the Company’s product candidates, the size of the potential markets for the Company’s product candidates, the ability of the Company’s partnerships to accelerate clinical development and the Company’s projected cash runway. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 12, 2026. The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

Investor Contact:

Silas Newcomb
Orchestra BioMed
[email protected]

Media Contact:

Nina Premutico
Orchestra BioMed
[email protected]

ORCHESTRA BIOMED HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
(Unaudited)
       
  September 30,    December 31, 
  2026
  2025
ASSETS          
CURRENT ASSETS:          
Cash and cash equivalents $ 27,761     $ 34,690  
Marketable securities   74,146       71,822  
Accounts receivable, net   56       95  
Inventory   221       310  
Prepaid expenses and other current assets   987       994  
Total current assets   103,171       107,911  
Property and equipment, net   2,284       1,715  
Right-of-use assets   1,001       1,496  
Strategic investments   —       2,495  
Deposits and other assets   1,280       1,240  
TOTAL ASSETS $ 107,736     $ 114,857  
           
LIABILITIES, SERIES A PREFERRED STOCK AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES:          
Accounts payable $ 5,030     $ 6,095  
Accrued expenses and other liabilities   8,367       9,890  
Operating lease liability, current portion   831       751  
Total current liabilities   14,228       16,736  
Royalty purchase agreement   36,795       16,482  
Note payable   21,152       —  
Loan payable   14,462       14,268  
Derivative liability   1,593       2,749  
Operating lease liability, less current portion   304       936  
Other long-term liabilities   456       308  
TOTAL LIABILITIES   88,990       51,479  
           
Series A Preferred Stock, $0.0001 par value per share; 200,000 issued and outstanding at September 30, 2026 and December 31, 2025; aggregate liquidation preference of $20,000   10,964       9,808  
           
STOCKHOLDERS’ EQUITY          
Preferred stock, $0.0001 par value, 10,000,000 shares authorized   —       —  
Common stock, $0.0001 par value per share; 340,000,000 shares authorized; 61,453,041 and 57,032,963 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively.   6       6  
Additional paid-in capital   433,704       416,083  
Accumulated other comprehensive (loss) income   (153 )     60  
Accumulated deficit   (425,775 )     (362,579 )
TOTAL STOCKHOLDERS’ EQUITY   7,782       53,570  
TOTAL LIABILITIES, SERIES A PREFERRED STOCK AND STOCKHOLDERS’ EQUITY $ 107,736     $ 114,857  

ORCHESTRA BIOMED HOLDINGS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(Unaudited)
   
  Three Months Ended September 30, 
  2026
  2025
Revenue:          
Partnership revenue $ —     $ 721  
Product revenue   91       140  
Total revenue   91       861  
Expenses:          
Cost of product revenues   28       49  
Research and development   17,734       14,027  
Selling, general and administrative   5,625       7,098  
Total expenses   23,387       21,174  
Loss from operations   (23,296 )     (20,313 )
Other income (expense):          
Interest expense, net   (2,463 )     (515 )
Change in the fair value of derivative liability   867       —  
Gain on sale of strategic investments   6,142       —  
Total other income (expense)   4,546       (515 )
Net loss   (18,750 )     (20,828 )
Adjustment to carrying value of Series A Preferred Stock   (867 )     —  
Net loss attributable to common stockholders $ (19,617 )   $ (20,828 )
           
Net loss attributable to common stockholders per share          
Basic and diluted $ (0.30 )   $ (0.40 )
Weighted-average shares used in computing net loss attributable to common stockholders per share, basic and diluted   64,620,127       52,186,503  
Comprehensive loss          
Net loss $ (18,750 )   $ (20,828 )
Unrealized (loss) gain on marketable securities   (72 )     29  
Comprehensive loss $ (18,822 )   $ (20,799 )



BrightView Reports Fourth Quarter and Fiscal 2026 Results With Third Consecutive Quarter of Land Maintenance Revenue Growth; Introduces Fiscal 2027 Guidance Underpinned by Margin Expansion and Accelerated Growth in Recurring Land Business

BrightView Reports Fourth Quarter and Fiscal 2026 Results With Third Consecutive Quarter of Land Maintenance Revenue Growth; Introduces Fiscal 2027 Guidance Underpinned by Margin Expansion and Accelerated Growth in Recurring Land Business

BLUE BELL, Pa.–(BUSINESS WIRE)–
BrightView Holdings, Inc. (NYSE: BV) (the “Company” or “BrightView”), the leading commercial landscaping services company in the United States, today reported unaudited results for the three months and full fiscal year ended September 30, 2026.

  • Fourth quarter net service revenue decreased 3.6% year-over-year to $677.3 million,
  • Fourth quarter Maintenance Services revenue increased 3.2% year-over-year to $495.7 million,
  • Fourth quarter Development Services revenue decreased 17.8% year-over-year to $184.2 million,
  • Full year net service revenue increased 1.5% year-over-year to $2.7 billion,
  • Full year Maintenance Services revenue increased 6% year-over-year to $2.0 billion, including Land Maintenance revenue increase of 1.9%,
  • Full year Development Services revenue decreased 9.4% year-over-year to $714.9 million,
  • Repurchased 1.2 million shares in the fourth quarter of fiscal 2026, bringing full year repurchases to 4.1 million shares.

“We closed fiscal 2026 with our third consecutive quarter of Land Maintenance revenue growth,” said Dale Asplund, BrightView President and Chief Executive Officer. “The underlying growth rate accelerated each quarter, reaching 3.3% in the fourth quarter, as improved customer retention and continued investment in our salesforce supported momentum in this highly recurring and predictable segment. For the full year, revenue increased 1.5%, and excluding the impact of non-routine items, Adjusted EBITDA improved modestly. Despite the macroeconomic environment driving softness in our Development business, we remain highly encouraged by the continued improvement in our foundational KPIs and remain focused on delivering long-term profitable growth and shareholder value. We enter fiscal 2027 expecting 3% to 4% growth in our recurring Land Maintenance business and a return to Adjusted EBITDA margin expansion, a testament to the progress we’ve made since the beginning of our transformation.”

Company Provides Fiscal Year 2027 Guidance1

 

 

Range

Comment

Land Maintenance Revenue

~$1.763 – $1.780 billion

~+3% to +4%

Snow Removal Revenue

~$210 – $230 million

Approximate 5-year average

Development Services Revenue

~$572 – $715 million

~(20%) – flat

Total Revenue

~$2.535 – $2.720 billion

 

Adjusted EBITDA2

$335 – $355 million

~13.2% or + ~110 bps margin expansion

Adjusted Free Cash Flow2

$110 – $130 million

 

 

1For assumptions underlying the 2027 guidance, see the Q4 2026 presentation at investor.brightview.com

2 Adjusted EBITDA, Adjusted EBITDA margin, and adjusted free cash flow are non-GAAP measures. Refer to the “Non-GAAP Financial Measures” section for more information. The Company is not providing a quantitative reconciliation of its financial outlook for Adjusted EBITDA to net income or adjusted free cash flow to net cash provided by operating activities, their corresponding GAAP measures, because the respective GAAP measures that are excluded from the non-GAAP financial outlook are difficult to reliably predict or estimate without unreasonable effort due to the dependence on future uncertainties, such as items discussed below. Additionally, information that is currently not available to the Company could have a potentially unpredictable and potentially significant impact on its future GAAP financial results.

Fiscal 2026 Results – Total BrightView

 
 

Total BrightView – Operating Highlights

 

($ in millions, except per share figures)

 

Three Months Ended

September 30,

 

 

Year Ended

September 30,

 

 

2026

 

2025

 

Change

 

 

2026

 

2025

 

Change

 

Revenue

 

$

677.3

 

$

702.8

 

 

(3.6

%)

 

$

2,712.6

 

$

2,672.8

 

 

1.5

%

Net Income

 

$

8.3

 

$

27.7

 

 

(70.0

%)

 

$

1.0

 

$

56.0

 

 

(98.2

%)

Net Income Margin

 

 

1.2

%

 

3.9

%

(270) bps

 

 

 

0.0

%

 

2.1

%

(210) bps

 

Adjusted EBITDA

 

$

100.3

 

$

113.5

 

 

(11.6

%)

 

$

328.9

 

$

352.3

 

 

(6.6

%)

Adjusted EBITDA Margin

 

 

14.8

%

 

16.1

%

(130) bps

 

 

 

12.1

%

 

13.2

%

(110) bps

 

Net income (loss) available to common shareholders

 

$

(0.7

)

$

11.9

 

 

(105.9

%)

 

$

(34.8

)

$

12.8

 

 

(371.9

%)

Weighted average number of common shares outstanding

 

 

92.2

 

 

94.8

 

 

(2.7

%)

 

 

93.5

 

 

95.2

 

 

(1.8

%)

Basic Earnings per Share

 

$

(0.01

)

$

0.13

 

 

(107.7

%)

 

$

(0.37

)

$

0.13

 

 

(384.6

%)

Adjusted Net Income

 

$

25.8

 

$

40.6

 

 

(36.5

%)

 

$

62.3

 

$

113.2

 

 

(45.0

%)

Adjusted weighted average number of common shares outstanding

 

 

146.5

 

 

149.0

 

 

(1.7

%)

 

 

147.7

 

 

149.4

 

 

(1.1

%)

Adjusted Earnings per Share

 

$

0.18

 

$

0.27

 

 

(33.3

%)

 

$

0.42

 

$

0.76

 

 

(44.7

%)

 

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Free Cash Flow, Adjusted Earnings per Share, and Adjusted weighted average number of common shares outstanding are non-GAAP measures. Refer to the “Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Financial Measures” sections for more information.

For the three months ended September 30, 2026, total revenue decreased 3.6% to $677.3 million, from $702.8 million in the 2025 period. The decrease was driven by a $39.9 million decrease in Development Services, partially offset by a $15.3 million increase in Maintenance Services.

For the fiscal year ended September 30, 2026, total revenue increased 1.5% to $2,712.6 million, from $2,672.8 million in the 2025 period. The increase was driven by an increase in Maintenance Services, driven by a $82.2 million increase in snow removal revenue and $31.1 million increase in commercial landscaping services. The increases were partially offset by a $74.2 million decrease in our Development Services revenues.

Fiscal 2026 Results – Segments

 
   

Maintenance Services – Operating Highlights

 

 

 

Three Months Ended

September 30,

 

 

Year Ended

September 30,

 

($ in millions)

 

2026

 

2025

 

Change

 

 

2026

 

2025

 

Change

 

Landscape Maintenance

 

$

496.2

 

$

480.3

 

 

3.3

%

 

$

1,711.6

 

$

1,680.5

 

 

1.9

%

Snow Removal

 

$

(0.5

)

$

0.1

 

 

(600.0

%)

 

$

293.0

 

$

210.8

 

 

39.0

%

Total Revenue

 

$

495.7

 

$

480.4

 

 

3.2

%

 

$

2,004.6

 

$

1,891.3

 

 

6.0

%

Adjusted EBITDA

 

$

73.6

 

$

72.8

 

 

1.1

%

 

$

241.7

 

$

245.5

 

 

(1.5

%)

Adjusted EBITDA Margin

 

 

14.8

%

 

15.2

%

(40) bps

 

 

 

12.1

%

 

13.0

%

(90) bps

 

Capital Expenditures

 

$

36.6

 

$

39.6

 

 

(7.6

%)

 

$

193.9

 

$

205.0

 

 

(5.4

%)

For the fourth quarter of fiscal 2026, revenue in the Maintenance Services Segment increased by $15.3 million, or 3.2%, from the prior year, underpinned by an increase in commercial landscape services as a result of increases in ancillary services and contract revenue.

Adjusted EBITDA for the Maintenance Services Segment for the three months ended September 30, 2026 increased by $0.8 million to $73.6 million from $72.8 million in the 2025 period. Segment Adjusted EBITDA Margin decreased 40 basis points to 14.8% in the three months ended September 30, 2026 from 15.2% in the 2025 period. The increase in Segment Adjusted EBITDA and decrease in Adjusted EBITDA Margin was primarily driven by higher revenues described above, partially offset by higher fuel prices and continued investments in our sales force.

For the fiscal year ended September 30, 2026, revenue in the Maintenance Services Segment increased by $113.3 million, or 6.0%, from the 2025 period. Snow removal services increased by $82.2 million, or 39.0%, and commercial landscaping services increased $31.1 million, or 1.9%. The increase in commercial landscaping services revenue was driven by increases in contract and ancillary services revenues.

Adjusted EBITDA for the Maintenance Services Segment for the fiscal year ended September 30, 2026 decreased by $3.8 million to $241.7 million from $245.5 million in the 2025 period. Segment Adjusted EBITDA Margin decreased 90 basis points to 12.1% in the year ended September 30, 2026, from 13.0% in the 2025 period. The decreases in Segment Adjusted EBITDA and Adjusted EBITDA Margin were primarily driven by a non-routine self-insurance adjustment and continued investments in our sales force, partially offset by increased snow removal services and commercial landscaping revenue described above.

Development Services – Operating Highlights

 

 

 

Three Months Ended

September 30,

 

 

Year Ended

September 30,

 

($ in millions)

 

2026

 

2025

 

Change

 

 

2026

 

2025

 

Change

 

Revenue

 

$

184.2

 

$

224.1

 

 

(17.8

%)

 

$

714.9

 

$

789.1

 

 

(9.4

%)

Adjusted EBITDA

 

$

26.7

 

$

40.7

 

 

(34.4

%)

 

$

87.2

 

$

106.8

 

 

(18.4

%)

Adjusted EBITDA Margin

 

 

14.5

%

 

18.2

%

(370) bps

 

 

 

12.2

%

 

13.5

%

(130) bps

 

Capital Expenditures

 

$

9.7

 

$

18.8

 

 

(48.4

%)

 

$

31.1

 

$

49.2

 

 

(36.8

%)

For the fourth quarter of fiscal 2026, revenue in the Development Services Segment decreased by $39.9 million, or 17.8%, compared to the prior year. The decrease was driven by decreased project volumes impacted by the timing and mix of projects.

Adjusted EBITDA for the Development Services Segment for the three months ended September 30, 2026 decreased $14.0 million to $26.7 million compared to the 2025 period and Adjusted EBITDA Margin decreased 370 basis points to 14.5% for the quarter from 18.2% in the prior year. The decrease in Segment Adjusted EBITDA was primarily driven by the decrease in revenue described above. The decrease in Segment Adjusted EBITDA Margin was primarily driven by the increased labor and material costs as a percentage of revenue.

For the fiscal year ended September 30, 2026, revenue in the Development Services Segment decreased by $74.2 million, or 9.4%, compared to the 2025 period. The decrease was driven by decreased project volumes impacted by the timing and mix of projects.

Adjusted EBITDA for the Development Services Segment fiscal year ended September 30, 2026 decreased $19.6 million to $87.2 million compared to the 2025 period. Segment Adjusted EBITDA Margin decreased 130 basis points to 12.2% for the period from 13.5% in the 2025 period. The decrease in Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin were primarily driven by revenue described above, as well as a non-routine self-insurance adjustment and increased investments in our sales force.

Total BrightView Cash Flow Metrics

 

 

Year Ended

September 30,

($ in millions)

 

2026

 

2025

 

Change

Net Cash Provided by Operating Activities

 

$

184.7

 

$

291.8

 

(36.7%)

Adjusted Free Cash Flow

 

$

(2.2

)

$

65.2

 

(103.4%)

Capital Expenditures

 

$

225.0

 

$

254.2

 

(11.5%)

Net Capital Expenditures

 

$

186.9

 

$

226.6

 

(17.5%)

 

Net Capital Expenditures is a non-GAAP financial measure. Refer to the “Non-GAAP Financial Measures” and “Reconciliation of GAAP to Non-GAAP Financial Measures” sections for more information

Net cash provided by operating activities for the fiscal year ended September 30, 2026 decreased $107.1 million to $184.7 million from $291.8 million in the prior year. This decrease was due to a decrease in net income adjusted for non-cash activities, combined with decreases in cash provided by unbilled and deferred revenue, accounts receivable, and accounts payable and other operating liabilities.

Adjusted Free Cash Flow decreased $67.4 million to an outflow of $2.2 million for the fiscal year ended September 30, 2026 from an inflow of $65.2 million in the prior year. The decrease in Adjusted Free Cash Flow was due to a decrease in net cash provided by operating activities partially offset by a decrease in cash used for capital expenditures and an increase in proceeds from sale of property and equipment, each as described above.

For the fiscal year ended September 30, 2026, capital expenditures were $225.0 million compared with $254.2 million in the 2025 period. The Company also generated proceeds from the sale of property and equipment of $38.1 million and $27.6 million during the fiscal year ended September 30, 2026 and 2025, respectively. Net of the proceeds from the sale of property and equipment, net capital expenditures represented 6.9% and 8.5% of revenue in the fiscal year ended September 30, 2026 and 2025, respectively.

Total BrightView Balance Sheet Metrics

($ in millions)

 

September 30,

2026

 

September 30,

2025

 

September 30, 2024

Long-term debt, net

 

$

882.1

 

$

790.2

 

$

802.5

Total Financial Debt1

 

 

1,017.5

 

 

877.4

 

 

877.3

Minus:

 

 

 

 

 

 

Total Cash & Equivalents

 

 

3.6

 

 

74.5

 

 

140.4

Total Net Financial Debt2

 

$

1,013.9

 

$

802.9

 

$

736.9

Total Net Financial Debt to Adjusted EBITDA ratio3

 

3.1x

 

2.3x

 

2.3x

1Total Financial Debt includes total long-term debt, net of original issue discount, and finance lease obligations

2Total Net Financial Debt equals Total Financial Debt minus Total Cash & Equivalents

3Total Net Financial Debt to Adjusted EBITDA ratio equals Total Net Financial Debt divided by the trailing twelve month Adjusted EBITDA.

As of September 30, 2026, the Company’s Total Net Financial Debt was $1,013.9 million, an increase of $211.0 million compared to $802.9 million as of September 30, 2025. The Company’s Total Net Financial Debt to Adjusted EBITDA ratio was 3.1x, 2.3x, and 2.3x as of September 30, 2026, September 30, 2025, and September 30, 2024 respectively. The year-over-year increase in Total Net Financial Debt was primarily driven by the increase in the Company’s Total Financial Debt, combined with the decrease in the Company’s Cash & Equivalents.

Conference Call Information

A conference call to discuss the fourth quarter and full year fiscal 2026 financial results is scheduled for November 11, 2026, at 8:30 a.m. EST. The U.S. toll free dial-in for the conference call is (800) 309-3473 and the international dial-in is (785) 838-9251. The access code is BRIGHT. A live audio webcast of the conference call will be available on the Company’s investor website https://investor.brightview.com, where presentation materials will be posted prior to the call. A replay of the call will be available until 11:59 p.m. EST on November 25, 2026. To access the recording, dial (800) 839-2418 (access code 27525).

About BrightView

BrightView (NYSE: BV), the nation’s largest commercial landscaper, proudly designs, creates, and maintains the best landscapes on Earth and provides the most efficient and comprehensive snow and ice removal services. With a dependable service commitment, BrightView brings brilliant landscapes to life at premier properties across the United States, including business parks and corporate offices, homeowners’ associations, healthcare facilities, educational institutions, retail centers, resorts and theme parks, municipalities, golf courses, and sports venues. BrightView also serves as Field Consultant to Major League Baseball. Through industry-leading best practices and sustainable solutions, BrightView is invested in taking care of our team members, engaging our clients, inspiring our communities, and preserving our planet. Visit www.BrightView.com and connect with us on X, Facebook, and LinkedIn.

Forward Looking Statements

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements relating to our fiscal 2027 guidance and other statements related to our goals, beliefs, business outlook, business trends, expectations regarding our industry, strategy, future events, future operations, future liquidity and financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as “outlook,” “guidance,” “projects,” “continues,” “believes,” “expects,” “may,” “will,” “should,” “seeks,” “intends,” “plans,” “estimates,” or “anticipates,” or the negative variations of these words or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. By their nature, forward-looking statements: speak only as of the date they are made; are not statements of historical fact or guarantees of future performance, and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which are subject to risks, uncertainties, assumptions, changes in circumstances or other factors outside of the Company’s control that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Factors that could cause actual results to differ materially from those projected include, but are not limited to; competitive industry pressures; our ability to preserve long-term customer relationships; a determination by customers to reduce their outsourcing or use of preferred vendors; inconsistent practices and the operating results of individual branches; our ability to implement our business strategies and achieve our growth objectives; negative impacts of future acquisitions or other strategic transactions; the seasonal nature of our landscape maintenance services; our dependence on weather conditions and the impact of severe weather and climate change on our business; any failure to accurately estimate the overall risk, requirements, or costs when we bid on or negotiate contracts that are ultimately awarded to us and, for such contracts, the ability to collect amounts owed under such contracts; the conditions and periodic fluctuations of the new commercial construction sector, as well as spending on repair and upgrade activities; the level, timing and location of snowfall; our ability to retain or hire our executive management and other key personnel; our ability to attract, retain and maintain positive relations with workers; any failure to properly verify employment eligibility of our employees; the liability exposure from our use of subcontractors to perform work under certain customer contracts; our recognition of future impairment charges; failure to comply with laws and governmental regulations including those relating to employees, the environment, immigration, human health, safety or transportation, which may result in lawsuits, investigations, restrictions or significant financial costs; the distraction and impact caused by litigation, of adverse litigation judgments and settlements resulting from legal proceedings; tax increases and changes in tax rules; any increase in on-job accidents involving employees; any failure, inadequacy, interruption, security failure or breach of our information technology systems; any adverse consequences of our substantial indebtedness; increases in interest rates governing our variable rate indebtedness increasing the cost of servicing our substantial indebtedness; risks related to counterparty credit worthiness or non-performance of the derivative financial instruments we utilize; restrictions within our debt agreements that limit our flexibility in operating; our ability to generate sufficient cash flow to satisfy our significant debt service obligations; the possibility to incur substantially more debt, including off-balance sheet financing, contractual obligations and general and commercial liabilities; any failure to extend credit under our facility or reduce the borrowing base under our Revolving Credit Facility; any future sales, or the perception of future sales, by us or our affiliates, which could cause the market price for our common stock to decline; the ability of KKR and One Rock to exert significant influence over us; anti-takeover provisions in our organizational documents that could delay or prevent a change in control; the ability of our Board of Directors to issue and designate shares of our preferred stock in additional series without stockholder approval; the fact that the holders of our Series A Preferred Stock may have different interests from and vote their shares in a manner deemed adverse to, holders of our common stock; the dividend, liquidation, and redemption rights of the holders of our Series A Preferred Stock; our certificate of incorporation restricting all stockholder litigation matters to the Court of Chancery of the State of Delaware and the federal district courts of the United States of America; general business, economic, and financial market conditions; increases in raw material costs, fuel prices, wages and other operating costs, and changes in our ability to source adequate supplies and materials in a timely manner; occurrence of natural disasters, terrorist attacks, global health emergencies and other external events; heightened inflation, geopolitical conflicts, recession, financial market disruptions, and other economic conditions; significant changes in our stock price and its ability for resale; securities analysts’ reports about our business or their downgrade of our stock or sector; maintaining effective internal controls; and costs and requirements imposed as a result of maintaining compliance with the requirements of being a public company. Our ability to affect repurchases under the share repurchase program may be impacted by changes in stock price, corporate or other economic or market conditions; the timing, manner and volume of repurchases of common shares pursuant to the repurchase program may be impacted by these and other factors.

Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found under “Item 1A. Risk Factors” in our Form 10-K for the fiscal year ended September 30, 2026, and such factors may be updated from time to time in our periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any forward-looking statement made in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Non-GAAP Financial Measures

To supplement the Company’s financial information presented in accordance with GAAP and aid understanding of the Company’s business performance, the Company uses certain non-GAAP financial measures, namely “Adjusted EBITDA”, “Adjusted EBITDA Margin”, “Adjusted Net Income (Loss)”, “Adjusted Earnings (Loss) per Share”, “Adjusted Free Cash Flow”, “Net Capital Expenditures”, “Total Financial Debt”, “Total Net Financial Debt” and “Total Net Financial Debt to Adjusted EBITDA ratio”. We believe Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Net Capital Expenditures, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio assist investors in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management regularly uses these measures as tools in evaluating our operating performance, financial performance and liquidity. Management uses Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Net Capital Expenditures, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio to supplement comparable GAAP measures in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. In addition, we believe that Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Net Capital Expenditures, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio are frequently used by investors and other interested parties in the evaluation of issuers, many of which also present Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Net Capital Expenditures, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio when reporting their results in an effort to facilitate an understanding of their operating and financial results and liquidity. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

Adjusted EBITDA: We define Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization, as further adjusted to exclude certain non-cash, non-recurring and other adjustment items.

Adjusted EBITDA Margin: We define Adjusted EBITDA Margin as Adjusted EBITDA, defined above, divided by Net Service Revenues.

Adjusted Net Income: We define Adjusted Net Income as net income (loss) including interest and depreciation, and excluding other items used to calculate Adjusted EBITDA and further adjusted for the tax effect of these exclusions and the removal of the discrete tax items.

Adjusted Earnings per Share: We define Adjusted Earnings per Share as Adjusted Net Income divided by the (i) weighted average number of common shares outstanding used in the calculation of basic earnings per share plus (ii) shares of common stock related to the Series A Preferred Stock on an as-converted basis, assumed to be converted for the entire period. The addition of shares of common stock related to the Series A Convertible Preferred Stock on an as-converted basis reflects the dilutive impact of the potential conversion of the Series A Preferred Stock and is expected to provide comparability in future periods.

Adjusted Free Cash Flow: We define Adjusted Free Cash Flow as cash flows from operating activities less capital expenditures, net of proceeds from the sale of property and equipment.

Net Capital Expenditures: We define Net Capital Expenditures as capital expenditures net of proceeds from the sale of property and equipment

Total Financial Debt: We define Total Financial Debt as total long-term debt, net of original issue discount, and finance/capital lease obligations.

Total Net Financial Debt: We define Total Net Financial Debt as Total Financial Debt minus total cash and cash equivalents.

Total Net Financial Debt to Adjusted EBITDA ratio: We define Total Net Financial Debt to Adjusted EBITDA ratio as Total Net Financial Debt divided by the trailing twelve month Adjusted EBITDA.

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Net Capital Expenditures, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or the ratio of net income (loss) to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of Adjusted Free Cash Flow available for management’s discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to the same or other similarly titled measures of other companies and can differ significantly from company to company

BrightView Holdings, Inc.

Consolidated Balance Sheets

(Unaudited)

 

(in millions)*

 

September 30,

2026

 

 

September 30,

2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

3.6

 

 

$

74.5

 

Accounts receivable, net

 

 

389.1

 

 

 

393.1

 

Unbilled revenue

 

 

118.9

 

 

 

113.1

 

Other current assets

 

 

93.4

 

 

 

85.6

 

Total current assets

 

 

605.0

 

 

 

666.3

 

Property and equipment, net

 

 

636.4

 

 

 

541.6

 

Intangible assets, net

 

 

44.7

 

 

 

66.5

 

Goodwill

 

 

2,015.7

 

 

 

2,015.7

 

Operating lease assets

 

 

77.3

 

 

 

72.1

 

Other assets

 

 

46.2

 

 

 

29.8

 

Total assets

 

$

3,425.3

 

 

$

3,392.0

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

125.6

 

 

$

137.7

 

Current portion of long-term debt

 

 

7.4

 

 

 

—

 

Deferred revenue

 

 

64.6

 

 

 

87.6

 

Current portion of self-insurance reserves

 

 

62.6

 

 

 

52.3

 

Accrued expenses and other current liabilities

 

 

181.7

 

 

 

212.2

 

Current portion of operating lease liabilities

 

 

25.7

 

 

 

24.7

 

Total current liabilities

 

 

467.6

 

 

 

514.5

 

Long-term debt, net

 

 

882.1

 

 

 

790.2

 

Deferred tax liabilities

 

 

73.5

 

 

 

63.8

 

Self-insurance reserves

 

 

122.6

 

 

 

122.8

 

Long-term operating lease liabilities

 

 

57.2

 

 

 

53.5

 

Other liabilities

 

 

88.1

 

 

 

47.1

 

Total liabilities

 

 

1,691.1

 

 

 

1,591.9

 

Mezzanine equity:

 

 

 

 

 

 

Series A convertible preferred shares, $0.01 par value, 7% cumulative dividends; 500,000 shares issued and outstanding as of September 30, 2026 and September 30, 2025, aggregate liquidation preference of $512.0 as of September 30, 2026 and September 30, 2025

 

 

507.1

 

 

 

507.1

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.01 par value; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2026 and September 30, 2025

 

 

—

 

 

 

—

 

Common stock, $0.01 par value; 500,000,000 shares authorized; 111,400,000 and 110,000,000 shares issued and 91,700,000 and 94,800,000 shares outstanding as of September 30, 2026 and September 30, 2025, respectively

 

 

1.1

 

 

 

1.1

 

Treasury stock, at cost; 19,700,000 and 15,200,000 shares as of September 30, 2026 and September 30, 2025, respectively

 

 

(255.0

)

 

 

(197.8

)

Additional paid-in capital

 

 

1,486.2

 

 

 

1,503.5

 

Accumulated deficit

 

 

(11.9

)

 

 

(12.9

)

Accumulated other comprehensive income (loss)

 

 

6.7

 

 

 

(0.9

)

Total stockholders’ equity

 

 

1,227.1

 

 

 

1,293.0

 

Total liabilities, mezzanine equity and stockholders’ equity

 

$

3,425.3

 

 

$

3,392.0

 

 

(*) Amounts may not total due to rounding.

BrightView Holdings, Inc.

Consolidated Statements of Operations

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Fiscal Year Ended September

30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

(in millions)*

 

 

 

 

 

 

 

 

 

 

 

 

Net service revenues

 

$

677.3

 

 

$

702.8

 

 

$

2,712.6

 

 

$

2,672.8

 

Cost of services provided

 

 

528.2

 

 

 

526.3

 

 

 

2,159.7

 

 

 

2,051.1

 

Gross profit

 

 

149.1

 

 

 

176.5

 

 

 

552.9

 

 

 

621.7

 

Selling, general and administrative expense

 

 

110.6

 

 

 

114.3

 

 

 

456.3

 

 

 

457.8

 

Amortization expense

 

 

5.1

 

 

 

7.0

 

 

 

21.8

 

 

 

29.3

 

Income from operations

 

 

33.4

 

 

 

55.2

 

 

 

74.8

 

 

 

134.6

 

Other expense (income)

 

 

0.4

 

 

 

(0.5

)

 

 

9.3

 

 

 

(0.4

)

Interest expense, net

 

 

13.3

 

 

 

13.4

 

 

 

55.4

 

 

 

53.7

 

Income before income taxes

 

 

19.7

 

 

 

42.3

 

 

 

10.1

 

 

 

81.3

 

Income tax expense

 

 

11.4

 

 

 

14.6

 

 

 

9.1

 

 

 

25.3

 

Net income

 

$

8.3

 

 

$

27.7

 

 

$

1.0

 

 

$

56.0

 

Less: dividends on Series A convertible preferred shares

 

 

9.0

 

 

 

9.0

 

 

 

35.8

 

 

 

35.8

 

Net income attributable to common stockholders

 

$

(0.7

)

 

$

18.7

 

 

$

(34.8

)

 

$

20.2

 

Earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

Basic (loss) earnings per share

 

$

(0.01

)

 

$

0.13

 

 

$

(0.37

)

 

$

0.13

 

Diluted (loss) earnings per share

 

$

(0.01

)

 

$

0.12

 

 

$

(0.37

)

 

$

0.13

 

BrightView Holdings, Inc.

Net Income Available to Common Shareholders

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Fiscal Year Ended September

30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

(in millions)*

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

8.3

 

 

$

27.7

 

 

$

1.0

 

 

$

56.0

 

Less: dividends on Series A convertible preferred shares

 

 

(9.0

)

 

 

(9.0

)

 

 

(35.8

)

 

 

(35.8

)

Net income attributable to common stockholders

 

$

(0.7

)

 

$

18.7

 

 

$

(34.8

)

 

$

20.2

 

Less: Earnings allocated to Convertible Preferred Shares

 

 

–

 

 

 

(6.8

)

 

 

–

 

 

 

(7.4

)

Net income available to common shareholders

 

$

(0.7

)

 

$

11.9

 

 

$

(34.8

)

 

$

12.8

 

 

(*) Amounts may not total due to rounding.

BrightView Holdings, Inc.

Segment Reporting

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Fiscal Year Ended September

30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

(in millions)*

 

 

 

 

 

 

 

 

 

 

 

 

Maintenance Services

 

$

495.7

 

 

$

480.4

 

 

$

2,004.6

 

 

$

1,891.3

 

Development Services

 

 

184.2

 

 

 

224.1

 

 

 

714.9

 

 

 

789.1

 

Eliminations

 

 

(2.6

)

 

 

(1.7

)

 

 

(6.9

)

 

 

(7.6

)

Net Service Revenues

 

$

677.3

 

 

$

702.8

 

 

$

2,712.6

 

 

$

2,672.8

 

Maintenance Services

 

$

73.6

 

 

$

72.8

 

 

$

241.7

 

 

$

245.5

 

Development Services

 

 

26.7

 

 

 

40.7

 

 

 

87.2

 

 

 

106.8

 

Adjusted EBITDA(1)

 

$

100.3

 

 

$

113.5

 

 

$

328.9

 

 

$

352.3

 

Maintenance Services

 

$

36.6

 

 

$

39.6

 

 

$

193.9

 

 

$

205.0

 

Development Services

 

 

9.7

 

 

 

18.8

 

 

 

31.1

 

 

 

49.2

 

Capital Expenditures

 

$

46.3

 

 

$

58.4

 

 

$

225.0

 

 

$

254.2

 

 

(*) Amounts may not total due to rounding.

BrightView Holdings, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Fiscal Year Ended

 

 

 

September 30,

2026

 

 

September 30,

2025

 

(in millions)*

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$

1.0

 

 

$

56.0

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation

 

 

186.5

 

 

 

142.2

 

Amortization of intangible assets

 

 

21.8

 

 

 

29.3

 

Amortization of financing costs and original issue discount

 

 

2.6

 

 

 

2.9

 

Loss on debt extinguishment

 

 

10.1

 

 

 

0.7

 

Deferred taxes

 

 

6.9

 

 

 

21.0

 

Equity-based compensation

 

 

17.5

 

 

 

18.2

 

Realized gain on hedges

 

 

(4.8

)

 

 

(5.4

)

Gain on disposal of property and equipment

 

 

(31.8

)

 

 

(23.7

)

Other non-cash activities

 

 

4.7

 

 

 

9.6

 

Change in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(1.0

)

 

 

12.2

 

Unbilled and deferred revenue

 

 

(28.8

)

 

 

28.4

 

Other operating assets

 

 

(2.2

)

 

 

(7.6

)

Accounts payable and other operating liabilities

 

 

2.2

 

 

 

8.0

 

Net cash provided by operating activities

 

 

184.7

 

 

 

291.8

 

Cash flows from investing activities:

 

 

 

 

 

 

Purchase of property and equipment

 

 

(225.0

)

 

 

(254.2

)

Proceeds from sale of property and equipment

 

 

38.1

 

 

 

27.6

 

Other investing activities

 

 

1.3

 

 

 

2.7

 

Net cash (used) by investing activities

 

 

(185.6

)

 

 

(223.9

)

Cash flows from financing activities:

 

 

 

 

 

 

Repayments of finance lease obligations

 

 

(53.9

)

 

 

(48.4

)

Repayments of term loan

 

 

(1.8

)

 

 

—

 

Repayments of receivables financing agreement

 

 

(44.7

)

 

 

(29.1

)

Proceeds from receivables financing agreement, net of issuance costs

 

 

144.5

 

 

 

14.5

 

Debt issuance and prepayment costs

 

 

(10.4

)

 

 

(1.3

)

Series A preferred stock dividend

 

 

(35.8

)

 

 

(35.8

)

Proceeds from issuance of common stock, net of share issuance costs

 

 

0.9

 

 

 

3.1

 

Repurchase of common stock and distributions

 

 

(56.9

)

 

 

(24.2

)

Contingent business acquisition payments

 

 

—

 

 

 

(0.5

)

(Decrease) increase in book overdrafts

 

 

(11.8

)

 

 

(12.1

)

Other financing activities

 

 

(0.1

)

 

 

—

 

Net cash (used) by financing activities

 

 

(70.0

)

 

 

(133.8

)

Net change in cash and cash equivalents

 

 

(70.9

)

 

 

(65.9

)

Cash and cash equivalents, beginning of period

 

 

74.5

 

 

 

140.4

 

Cash and cash equivalents, end of period

 

$

3.6

 

 

$

74.5

 

Supplemental Cash Flow Information:

 

 

 

 

 

 

Cash (received) paid for income taxes, net

 

$

(1.2

)

 

$

6.3

 

Cash paid for interest

 

$

54.6

 

 

$

56.7

 

Accrual for property and equipment

 

$

5.5

 

 

$

27.8

 

 

(*) Amounts may not total due to rounding.

BrightView Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

Fiscal Year Ended September 30,

 

(in millions)*

 

2026

 

 

2025

 

2026

 

 

2025

 

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

8.3

 

 

$

27.7

 

$

1.0

 

 

$

56.0

 

Plus:

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

13.3

 

 

 

13.4

 

 

55.4

 

 

 

53.7

 

Income tax expense

 

 

11.4

 

 

 

14.6

 

 

9.1

 

 

 

25.3

 

Depreciation expense

 

 

49.5

 

 

 

41.0

 

 

186.5

 

 

 

142.2

 

Amortization expense

 

 

5.1

 

 

 

7.0

 

 

21.8

 

 

 

29.3

 

Business transformation and integration costs (a)

 

 

8.2

 

 

 

5.0

 

 

27.1

 

 

 

26.1

 

Equity-based compensation (b)

 

 

4.2

 

 

 

4.8

 

 

17.9

 

 

 

19.0

 

Debt extinguishment (c)

 

 

0.3

 

 

 

—

 

 

10.1

 

 

 

0.7

 

Adjusted EBITDA

 

$

100.3

 

 

$

113.5

 

$

328.9

 

 

$

352.3

 

Adjusted Net Income

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

8.3

 

 

$

27.7

 

$

1.0

 

 

$

56.0

 

Plus:

 

 

 

 

 

 

 

 

 

 

 

Amortization expense

 

 

5.1

 

 

 

7.0

 

 

21.8

 

 

 

29.3

 

Business transformation and integration costs (a)

 

 

8.2

 

 

 

5.0

 

 

27.1

 

 

 

26.1

 

Equity-based compensation (b)

 

 

4.2

 

 

 

4.8

 

 

17.9

 

 

 

19.0

 

Debt extinguishment (c)

 

 

0.3

 

 

 

—

 

 

10.1

 

 

 

0.7

 

Income tax adjustment (d)

 

 

(0.3

)

 

 

(3.9

)

 

(15.6

)

 

 

(17.9

)

Adjusted Net Income

 

$

25.8

 

 

$

40.6

 

$

62.3

 

 

$

113.2

 

Adjusted Free Cash Flow

 

 

 

 

 

 

 

 

 

 

 

Cash flows provided by operating activities

 

$

56.7

 

 

$

84.4

 

$

184.7

 

 

$

291.8

 

Minus:

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

46.2

 

 

 

58.4

 

 

225.0

 

 

 

254.2

 

Plus:

 

 

 

 

 

 

 

 

 

 

 

Proceeds from sale of property and equipment

 

 

24.8

 

 

 

13.4

 

 

38.1

 

 

 

27.6

 

Adjusted Free Cash Flow

 

$

35.3

 

 

$

39.4

 

$

(2.2

)

 

$

65.2

 

Adjusted Earnings per Share

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

Adjusted Net Income (Loss)

 

$

25.8

 

 

$

40.6

 

$

62.3

 

 

$

113.2

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding – basic

 

 

92,235,000

 

 

 

94,778,000

 

 

93,494,000

 

 

 

95,170,000

 

Plus:

 

 

 

 

 

 

 

 

 

 

 

Dilutive impact of Series A convertible preferred stock as-converted

 

 

54,242,000

 

 

 

54,242,000

 

 

54,242,000

 

 

 

54,242,000

 

Adjusted weighted average number of common shares outstanding

 

 

146,477,000

 

 

 

149,020,000

 

 

147,736,000

 

 

 

149,412,000

 

Adjusted Earnings per Share

 

$

0.18

 

 

$

0.27

 

$

0.42

 

 

$

0.76

 

 

(*) Amounts may not total due to rounding.

BrightView Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

 

(a)

 

Business transformation and integration costs consist of (i) severance and related costs; (ii) business integration costs and (iii) information technology infrastructure, transformation and other costs.

 

 

Three Months Ended

September 30,

 

 

Fiscal Year Ended

September 30,

 

(in millions)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Severance and related costs

 

$

1.0

 

 

$

0.1

 

 

$

2.3

 

 

$

(0.4

)

Business integration (e)

 

 

—

 

 

 

0.7

 

 

 

0.3

 

 

 

0.8

 

IT infrastructure, transformation, and other (f)

 

 

7.2

 

 

 

4.2

 

 

 

24.5

 

 

 

25.7

 

Business transformation and integration costs

 

$

8.2

 

 

$

5.0

 

 

$

27.1

 

 

$

26.1

 

(b)

 

Represents equity-based compensation expense and related taxes recognized for equity incentive plans outstanding.

(c)

 

Represents losses on the extinguishment of debt related to Amendments No. 11, No. 10, and No. 9 to the Credit Agreement, and Amendment No. 6 to the Receivables Financing Agreement, in the fiscal years ended September 30, 2026 and 2025, respectively, and includes accelerated amortization of deferred financing fees and original issue discount as well as fees paid to lenders and third parties.

(d)

 

Represents the tax effect of pre-tax items excluded from Adjusted Net Income and the removal of the applicable discrete tax items, which collectively result in an increase or decrease in income tax. The tax effect of pre-tax items excluded from Adjusted Net Income is computed using the statutory rate related to the jurisdiction that was impacted by the adjustment after taking into account the impact of permanent differences and valuation allowances. Discrete tax items include changes in laws or rates, changes in uncertain tax positions relating to prior years and changes in valuation allowances.

 

 

Three Months Ended

September 30,

 

 

Year Ended

September 30,

 

(in millions)*

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Tax impact of pre-tax income adjustments

 

$

(0.9

)

 

$

3.8

 

 

$

15.1

 

 

$

17.8

 

Discrete tax items

 

 

1.2

 

 

 

0.1

 

 

 

0.5

 

 

 

0.1

 

Income tax adjustment

 

$

0.3

 

 

$

3.9

 

 

$

15.6

 

 

$

17.9

 

(e)

 

Represents isolated expenses specifically related to the integration of acquired companies such as one-time employee retention costs, employee onboarding and training costs, and fleet and uniform rebranding costs. The Company excludes business integration costs from the non-GAAP measures disclosed above since such expenses vary in amount due to the number of acquisitions and size of acquired companies as well as factors specific to each acquisition, and as a result lack predictability as to occurrence and/or timing, and create a lack of comparability between periods.

(f)

 

Represents expenses related to distinct initiatives, typically significant enterprise-wide changes, including actions taken as part of the Company’s One BrightView initiative. Such expenses are excluded from the measures disclosed above since such expenses vary in amount based on occurrence as well as factors specific to each of the activities, are outside of the normal operations of the business, and create a lack of comparability between periods.

BrightView Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

 

Net Capital Expenditures

 

 

 

 

 

 

 

 

 

(in millions)*

 

September 30,

2026

 

 

September 30,

2025

 

 

September 30,

2024

 

Capital Expenditures

 

$

225.0

 

 

$

254.2

 

 

$

78.4

 

Less:

 

 

 

 

 

 

 

 

 

Proceeds from sale of property and equipment

 

 

38.1

 

 

 

27.6

 

 

 

18.1

 

Net Capital Expenditures

 

$

186.9

 

 

$

226.6

 

 

$

60.3

 

Total Financial Debt and Total Net Financial Debt

 

 

 

 

 

 

 

 

 

(in millions)*

 

September 30,

2026

 

 

September 30,

2025

 

 

September 30,

2024

 

Long-term debt, net

 

$

882.1

 

 

$

790.2

 

 

$

802.5

 

Plus:

 

 

 

 

 

 

 

 

 

Current portion of long term debt

 

 

7.4

 

 

 

—

 

 

 

—

 

Financing costs, net

 

 

6.7

 

 

 

5.3

 

 

 

6.5

 

Present value of net minimum payment – finance lease obligations (g)

 

 

121.3

 

 

 

81.9

 

 

 

68.3

 

Total Financial Debt

 

 

1,017.5

 

 

 

877.4

 

 

 

877.3

 

Less: Cash and cash equivalents

 

 

(3.6

)

 

 

(74.5

)

 

 

(140.4

)

Total Net Financial Debt

 

$

1,013.9

 

 

$

802.9

 

 

$

736.9

 

Total Net Financial Debt to Adjusted EBITDA ratio

 

3.1x

 

 

2.3x

 

 

2.3x

 

(g)

 

Balance is presented within Accrued expenses and other current liabilities and Other liabilities in the Consolidated Balance Sheet.

(*)

 

Amounts may not total due to rounding.

 

For More Information:

Investor Relations

Chris Stoczko, Vice President of Finance

[email protected]

News Media

David Freireich, Vice President of Communications

[email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Landscape

MEDIA:

Logo
Logo

Lumexa Imaging Announces Third Quarter 2026 Results

RALEIGH, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) — Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the third quarter ended September 30, 2026.

“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “These achievements mark progress toward our long-term growth plans, and that progress is translating into strong, durable cash generation. We enter the fourth quarter confident in our ability to deliver for patients, partners, and shareholders.”

“We are leading a transformation in healthcare – delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”

Third Quarter 2026 Highlights

All comparisons are to the quarter ended September 30, 2025, unless otherwise noted

  • Revenue growth of 5.0% consolidated and 7.7% system-wide; consolidated revenues of $272.0 million as compared to $258.9 million
  • Advanced outpatient volume growth of 7.9% consolidated and 8.1% system-wide
  • Same-center advanced outpatient volume growth of 6.6% consolidated and 6.8% system-wide
  • Advanced procedure mix of 31.8% consolidated and 38.2% system-wide, up 127 and 145 basis points, respectively
  • Net income of $7.2 million as compared to net loss of $3.5 million
  • Adjusted EBITDA of $62.6 million as compared to $59.1 million; and a 23.0% Adjusted EBITDA margin as compared to 22.8%
  • GAAP EPS of $0.07 per share and Adjusted EPS of $0.26 per share

2026 Full Year Outlook:

Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.

  • Reiterating full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion.
  • Narrowing its full-year 2026 Adjusted EBITDA guidance range to $236 million to $240 million, from its prior range of $235 million to $241 million. The midpoint of $238 million is unchanged. This includes approximately $7 million of public company costs that were not incurred in 2025. (At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%)
  • Raising guidance for Adjusted EPS to $0.86 to $0.90 from $0.71 to $0.77 per share, driven by lower assumed effective tax rate.

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its third quarter 2026 results on November 10, 2026 at 5:00 p.m. ET. The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of Non-GAAP Financial Measures

This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use  Adjusted EBITDA and Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance; (ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and approximately 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; and our ability to drive future growth and execute on our goals and strategies. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form 10-K for the year ended December 31, 2025 and our later dated Quarterly Reports on Form 10-Q, each as filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

Investor Contact

Sue Dooley
Lumexa Imaging
[email protected]

Media Contact

Melissa Weston
Lumexa Imaging
[email protected]



Lumexa Imaging Q3 2026 Outpatient Volumes Highlights:

Consolidated 3Q26   3Q25    Increase YoY
  Consolidated total procedures 631,131   609,352   3.6%
  Consolidated advanced procedures 200,600   185,913   7.9%
  % advanced procedures 31.8%   30.5%   127bps
  Consolidated same-center advanced volume growth ——   ——   6.6%
System-wide          
  System-wide total procedures 1,049,491   1,009,029   4.0%
  System-wide advanced procedures 400,581   370,501   8.1%
  % advanced procedures 38.2%   36.7%   145bps
  System-wide same-center advanced volume growth ——   ——   6.8%
Note: Advanced Procedures includes MRI and CT modalities. As of September 30, 2026 Center count was 190 total, 87 JV and 103 consolidated.
             

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT FOR COMMON SHARES)
(Unaudited)
    September 30, 2026   December 31, 2025
         
ASSETS        
Cash and cash equivalents   $ 90,011     $ 58,828  
Accounts receivable     117,769       112,942  
Accounts receivable, related party     22,570       18,893  
Other receivables     33,174       19,015  
Prepaid expenses     14,789       17,582  
Total current assets     278,313       227,260  
Property and equipment, net of accumulated depreciation     158,847       144,709  
Operating lease right-of-use assets     74,833       76,555  
Investments in unconsolidated affiliates     428,019       423,191  
Intangible assets, net of accumulated amortization     38,582       41,335  
Goodwill     807,554       807,554  
Other assets     46,988       43,953  
TOTAL ASSETS   $ 1,833,136     $ 1,764,557  
LIABILITIES AND EQUITY        
Accounts payable   $ 20,382     $ 44,857  
Accrued expenses and other current liabilities     117,920       95,561  
Accounts receivable pledging arrangement     2,322       1,599  
Current portion of long-term debt     15,548       13,112  
Current portion of finance lease liabilities     15,007       11,552  
Current portion of operating lease liabilities     12,277       12,513  
Total current liabilities     183,456       179,194  
Long-term debt, less current maturities     821,524       819,029  
Long-term finance lease liabilities, less current maturities     39,782       33,262  
Long-term operating lease liabilities, less current maturities     70,377       71,437  
Deferred income taxes     47,044       40,772  
Other liabilities     36,870       34,740  
Total liabilities     1,199,053       1,178,434  
COMMITMENTS AND CONTINGENCIES        
EQUITY:        
Common stock, $0.001 par value, 1,000,000,000 shares
authorized, 96,062,177 shares issued and outstanding at
September 30, 2026 and 96,109,927 shares issued and
outstanding at December 31, 2025
    96       96  
Additional paid-in-capital     1,253,407       1,217,087  
Accumulated deficit     (619,420 )     (631,060 )
Total equity     634,083       586,123  
TOTAL LIABILITIES AND EQUITY   $ 1,833,136     $ 1,764,557  

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA)
(Unaudited)
         
    Three Months Ended September 30,
      2026     2025  
REVENUES:        
Net patient service revenue   $ 211,115   $ 201,695  
Management fee and other revenue     60,858     57,249  
Total revenues     271,973     258,944  
OPERATING EXPENSES:        
Cost of operations, excluding depreciation and amortization     225,571     219,236  
General and administrative expenses     30,025     17,081  
Depreciation and amortization     10,331     9,654  
Loss on disposal of property and equipment     779     623  
Total operating expenses     266,706     246,594  
Equity in earnings of unconsolidated affiliates     22,846     17,990  
INCOME FROM OPERATIONS     28,113     30,340  
OTHER EXPENSES:        
Interest expense     15,674     30,577  
Fair market value adjustment on debt     654     –  
Total other expenses     16,328     30,577  
INCOME (LOSS) BEFORE INCOME TAXES     11,785     (237 )
Income tax provision     4,607     3,264  
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)   $ 7,178   $ (3,501 )
         
Weighted average shares outstanding:        
Basic     95,983,246     69,531,530  
Diluted     96,256,077     69,531,530  
Net income (loss) per common share        
Basic   $ 0.07   $ (0.05 )
Diluted   $ 0.07   $ (0.05 )

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA)
(Unaudited)
         
    Nine Months Ended September 30,
      2026     2025  
REVENUES:        
Net patient service revenue   $ 612,168   $ 592,178  
Management fee and other revenue     176,504     163,169  
Total revenues     788,672     755,347  
OPERATING EXPENSES:        
Cost of operations, excluding depreciation and amortization     668,611     639,898  
General and administrative expenses     74,757     53,262  
Depreciation and amortization     30,336     27,984  
Loss on disposal of property and equipment     892     477  
Total operating expenses     774,596     721,621  
Equity in earnings of unconsolidated affiliates     56,489     49,835  
INCOME FROM OPERATIONS     70,565     83,561  
OTHER EXPENSES:        
Interest expense     48,227     90,523  
Loss on extinguishment and modification of debt     1,053     –  
Fair market value adjustment on debt     654     –  
Total other expenses     49,934     90,523  
INCOME (LOSS) BEFORE INCOME TAXES     20,631     (6,962 )
Income tax provision     8,991     11,452  
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)   $ 11,640   $ (18,414 )
         
Weighted average shares outstanding:        
Basic     95,983,242     69,527,181  
Diluted     96,092,916     69,527,181  
Net income (loss) per common share        
Basic   $ 0.12   $ (0.26 )
Diluted   $ 0.12   $ (0.26 )

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(Unaudited)
         
    Nine Months Ended September 30,
      2026       2025  
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income (loss)   $ 11,640     $ (18,414 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities        
Depreciation and amortization     30,336       27,984  
Amortization of operating lease right-of-use assets     11,879       11,162  
Amortization of debt issuance costs     2,161       4,337  
Amortization of cloud computing implementation costs     1,332       271  
Unrealized fair market value adjustment on debt     263       –  
Write-off of debt issuance costs related to extinguishment of debt     46       –  
Equity in earnings of unconsolidated affiliates     (56,489 )     (49,835 )
Distributions from investments in unconsolidated affiliates     55,028       41,223  
Loss on disposal of property and equipment     892       477  
Deferred income taxes     6,272       3,502  
Stock-based compensation     37,350       23,032  
Other     (1,030 )     –  
Changes in operating assets and liabilities:        
Accounts receivable     (4,827 )     (7,206 )
Accounts receivable, related party     (3,677 )     2,189  
Capitalized cloud computing implementation costs     (2,773 )     (1,686 )
Other receivables     (14,159 )     (7,494 )
Prepaid expenses     2,094       (6,369 )
Other assets     (2,196 )     (15,418 )
Accounts payable     (24,475 )     5,007  
Accrued expenses and other current liabilities     29,725       (10,889 )
Other liabilities     2,605       7,700  
Operating lease liabilities     (11,453 )     (9,602 )
Net cash provided by (used in) operating activities     70,544       (29 )
CASH FLOWS FROM INVESTING ACTIVITIES:        
Proceeds from sale or disposal of property and equipment     196       794  
Acquisition of intangible asset     (600 )     –  
Purchases of property and equipment     (29,192 )     (19,228 )
Contributions to investments in unconsolidated affiliates     (3,366 )     (123 )
Net cash used in investing activities     (32,962 )     (18,557 )
CASH FLOWS FROM FINANCING ACTIVITIES:        
Payment of third-party debt issuance costs     (154 )     –  
Proceeds from long-term debt     15,675       2,818  
Payments of long-term debt     (11,925 )     (11,807 )
Proceeds from revolving line of credit     –       5,000  
Payments of finance lease liabilities     (10,455 )     (4,926 )
Capital contributions     –       835  
Proceeds from accounts receivable pledging arrangement     1,080       726  
Repayments on accounts receivable pledging arrangement     (620 )     –  
Net cash used in financing activities     (6,399 )     (7,354 )
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS     31,183       (25,940 )
CASH AND CASH EQUIVALENTS, beginning of period     58,828       26,131  
CASH AND CASH EQUIVALENTS, end of period   $ 90,011     $ 191  

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(IN THOUSANDS)
(Unaudited)
         
    Three Months Ended September 30,
      2026       2025  
         
Net income (loss)   $ 7,178     $ (3,501 )
Depreciation and amortization     10,331       9,654  
Income tax provision     4,607       3,264  
Amortization of basis difference     573       500  
Interest expense     15,674       30,577  
Stock-based compensation     12,339       8,312  
Loss on disposal of property and equipment     779       623  
Fair market value adjustment on debt     654       –  
Severance and executive recruiting(1)     622       365  
Strategic initiatives and implementation(2)     2,365       1,198  
Transaction costs(3)     (661 )     2,899  
Litigation and settlements(4)     3,578       (14 )
Other(5)     362       728  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     4,194       4,525  
Adjusted EBITDA   $ 62,595     $ 59,130  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.                    
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.    
(6)To adjust for Lumexa Imaging’s proportional share of depreciation and amortization, interest expense and losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(IN THOUSANDS)
(Unaudited)
         
    Nine Months Ended September 30,
      2026     2025  
         
Net income (loss)   $ 11,640   $ (18,414 )
Depreciation and amortization     30,336     27,984  
Income tax provision     8,991     11,452  
Amortization of basis difference     1,678     1,500  
Interest expense     48,227     90,523  
Stock-based compensation     37,350     23,032  
Loss on extinguishment and modification of debt     1,053     –  
Loss on disposal of property and equipment     892     477  
Fair market value adjustment on debt     654     –  
Severance and executive recruiting(1)     2,253     2,538  
Strategic initiatives and implementation(2)     5,849     3,084  
Transaction costs(3)     2,628     10,363  
Litigation and settlements(4)     4,780     (142 )
Other(5)     444     886  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     13,464     13,121  
Adjusted EBITDA   $ 170,239   $ 166,404  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
(6)To adjust for Lumexa Imaging’s proportional share of depreciation and amortization, interest expense and losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(Unaudited)
         
    Three Months Ended September 30,
      2026       2025  
         
Net income (loss)   $ 7,178     $ (3,501 )
         
Stock-based compensation     12,339       8,312  
Loss on disposal of property and equipment     779       623  
Fair market value adjustment on debt     654       –  
Severance and executive recruiting(1)     622       365  
Strategic initiatives and implementation(2)     2,365       1,198  
Transaction costs(3)     (661 )     2,899  
Litigation and settlements(4)     3,578       (14 )
Other(5)     362       728  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     160       255  
Total adjustments     20,198       14,366  
Tax impact of adjustments(7)     (2,722 )     (1,515 )
Adjusted net income   $ 24,654     $ 9,350  
         
Weighted average shares outstanding        
Basic     95,983,246       69,531,530  
Diluted     96,256,077       69,531,530  
         
Adjusted basic net income per share   $ 0.26     $ 0.13  
Adjusted diluted net income per share   $ 0.26     $ 0.13  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
(6)To adjust for Lumexa Imaging’s proportional share of losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.
(7)Tax effected adjustments using blended federal and state effective income tax rate.

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(Unaudited)
         
    Nine Months Ended September 30,
      2026       2025  
         
Net income (loss)   $ 11,640     $ (18,414 )
         
Stock-based compensation     37,350       23,032  
Loss on disposal of property and equipment     892       477  
Loss on extinguishment and modification of debt     1,053       –  
Fair market value adjustment on debt     654       –  
Severance and executive recruiting(1)     2,253       2,538  
Strategic initiatives and implementation(2)     5,849       3,084  
Transaction costs(3)     2,628       10,363  
Litigation and settlements(4)     4,780       (142 )
Other(5)     444       886  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     755       309  
Total adjustments     56,658       40,547  
Tax impact of adjustments(7)     (7,183 )     (4,381 )
Adjusted net income   $ 61,115     $ 17,752  
         
Weighted average shares outstanding        
Basic     95,983,242       69,527,181  
Diluted     96,092,916       69,527,181  
         
Adjusted basic net income per share   $ 0.64     $ 0.26  
Adjusted diluted net income per share   $ 0.64     $ 0.26  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.                    
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.  
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
(6)To adjust for Lumexa Imaging’s proportional share of losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.
(7)Tax effected adjustments using blended federal and state effective income tax rate.

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
DETAILS OF MANAGEMENT FEE AND OTHER REVENUES
(IN THOUSANDS)
(Unaudited)
    Three Months Ended September 30,
      2026     2025
Components of “management fee and other revenues:”        
Fees for managing joint ventured outpatient sites and other third party services   $ 25,889   $ 23,843
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa     34,969     33,406
Total revenues   $ 60,858   $ 57,249
         
         
         
    Nine Months Ended September 30,
      2026     2025
Components of “management fee and other revenues:”        
Fees for managing joint ventured outpatient sites and other third party services   $ 73,490   $ 64,497
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa     103,014     98,672
Total revenues   $ 176,504   $ 163,169

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SEGMENT REVENUES
(IN THOUSANDS)
(Unaudited)
                 
                 
    THREE MONTHS ENDED SEPTEMBER 30, 2026
    OUTPATIENT   PROFESSIONAL   INTERSEGMENT

ELIMINATIONS
  TOTAL OF

REPORTABLE

SEGMENTS
Revenue                
Net patient service revenue   $ 148,975   $ 66,342   $ (4,202 )   $ 211,115
Management fee and other revenue     52,974     7,884     –       60,858
Total revenues   $ 201,949   $ 74,226   $ (4,202 )   $ 271,973